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ABSTRACT 
  
Incretins are gastric hormones released by intestinal K-cells in response to food 
consumption and stimulate insulin secretion from pancreatic beta cells. One of these 
hormones, glucose-dependent insulinotropic peptide (GIP) is also anabolic in bone. 
Individuals with diabetes experience diminished bone quality caused by a low bone 
formation osteopenia. The present study seeks to identify a mechanism for diabetic 
osteopenia in which diabetes interferes with GIP-stimulated increases in the collagen cross-
linking enzyme lysyl oxidase (LOX) in osteoblasts, leading to decreased collagen integrity 
and the trabecular abnormalities seen in diabetic bone. Micro-CT analysis and picrosirius 
red histology of long bones from LOX +/- and wild type mice made diabetic by low dose 
streptozotocin induction revealed a profound exacerbation of the decreased bone volume, 
impaired trabecular structure, and disorganized collagen matrix seen in diabetic mice when 
the mice were also haploinsufficient for LOX. Furthermore, qPCR of RNA isolated from 
diabetic long bones revealed a more than 20 fold decrease in LOX expression in diabetic 
bone from wild type mice. Treatment of wild type osteoblasts in culture with GIP results 
in a significant increase in LOX transcript and protein levels. Interestingly in our diabetic 
  v 
mice there is a decrease in osteoblast derived LOX and an abnormal increase in serum 
levels of the anti-incretin gut-derived dopamine, which is known to inhibit the effects of 
GIP in the pancreas. Therefore the ability of dopamine to inhibit GIP-stimulated signaling 
in osteoblasts was examined. Data indicate a strong dose-dependent inhibition of GIP-
stimulated LOX expression when primary osteoblast cultures are pretreated with 
dopamine. Finally, pretreatment of primary osteoblasts with the dopamine receptor 
inhibitor amisulpride restored the impaired GIP stimulated increases in LOX expression in 
osteoblasts isolated from diabetic mice. This study defines a potential mechanism for 
diabetic bone disease and suggests that interference with dopamine signaling would likely 
restore bone health in diabetes.  
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INTRODUCTION 
I. The Regulation and Structure of Bone 
Bone has many important biological functions in the human body that extend 
beyond the commonly associated roles of providing support for muscles and protecting 
vital organs. Bone is responsible for the storage of vital ions such as calcium, regulation 
of hematopoiesis, and performs endocrine functions by controlling phosphate metabolism 
and fat deposition. Unlike other durable structures, such as teeth, tendons, and cartilage, 
bone is continuously renewed by the process of bone remodeling in which old segments 
of bone are removed and replaced by specialized bone cells. This process requires highly 
intricate regulatory processes that must work in synchrony to maintain a healthy skeleton. 
Any alteration in this regulation can result in not only diseases of the bone, but systemic 
abnormalities as well. 
The specialized bone cells that perform remodeling are mainly the osteoblasts and 
the osteoclasts. Osteoblasts are terminally differentiated cells derived from the 
mesenchymal stem cell lineage located in the bone marrow, which also differentiate in to 
adipocytes and chondrocytes among other cells. They are found on the surface of bone in 
the periosteum and endosteum. Osteoblasts are the bone forming cells that secrete first an 
organic matrix composed primarily of type I collagen, and then deposit hydroxyapatite, 
the material that makes up the mineral. This occurs in a highly regulated and organized 
manner where hydroxyapatite crystals are deposited in to the organic matrix framework 
to create mineralized tissue (Simon 2007). Osteoclasts originate from hematopoietic stem 
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cells and are responsible for the removal of old, micro-fractured bone, a process known 
as bone resorption.  During resorption, osteoclasts create an acidic microenvironment and 
secrete various proteinases to dissolve both the mineral and organic phases of bone. 
Osteoclasts, like macrophages, which also originate from hematopoietic stem cells, are 
large (~ 100-200 μM in diameter) multinucleated cells and are found in resorption pits on 
the surface of bone (Ballanti et al. 1997). The number and activity of osteoblasts and 
osteoclasts determines the bone formation and resorption rate, respectively, and are 
maintained in balance in a healthy skeleton. Osteoblasts and stromal cells can regulate the 
number and activity of osteoclasts through expression of receptor activator of nuclear 
factor-κB-ligand (RANKL) and osteoprotegerin (OPG). RANKL, a member of the TNF 
family, is expressed on the surface of osteoblast and stromal cells. It is a ligand for 
RANK, a receptor expressed on osteoclast progenitor cells that upon activation stimulates 
osteoclast differentiation and activity. RANKL can also be secreted in a soluble form by 
immune cells such as macrophages, and it is this process that mediates inflammation 
based bone resorption (Boyce and Xing 2007). OPG is a soluble decoy receptor secreted 
by osteoblasts and other cells that binds to and sequesters RANKL, thereby preventing 
the activation of RANK and subsequent osteoclast differentiation. RANK, RANKL, and 
OPG production provide a way to couple osteoblast and osteoclast activity, ensuring the 
regulation of overall bone turnover (Cao et al. 2005). Systemic hormones as well as local 
factors also regulate the replication, differentiation, recruitment, and activity of 
osteoblasts and osteoclasts. Hormones can act on bone cells directly to control these 
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processes, or they can alter the synthesis, activation, and receptor binding of local factors 
such as growth factors, cytokines, and prostaglandins and leukotrienes (Simon 2007). 
Bone remodeling occurs throughout life and until the age of 30-35 remains in 
homeostasis, with the rate of resorption of old damaged bone compensated for by the rate 
of formation of new bone so the total amount of bone in the skeleton does not change. 
However there are certain situations where this balance is disrupted, most of which 
concern aging or disease. During childhood growth, an increase in bone formation rate 
over resorption rate results in a total increase in bone mass. Peak bone mass is reached by 
men and women at about the third decade of life and plateaus. Following the plateau 
phase begins a period of net bone loss of approximately 0.3% to 0.5% per year (Cao et al. 
2005). Women however have accelerated bone loss with age approximately 10 fold for 5 
to 7 years following menopause. Post-menopausal estrogen deficiency is the significant 
cause of this accelerated bone loss due to the osteoprotective nature of estrogen in 
women. Estrogen stimulates the expression of OPG in osteoblasts (Bord et al. 2003), 
resulting in the sequestration of RANKL from its receptor RANK and thereby preventing 
osteoclast differentiation, making it an anti-resorptive hormone. Therefore it follows that 
a decrease in OPG as a result of a decrease in estrogen will increase the available 
RANKL, resulting in an increase in osteoclast mediated bone resorption (Kapczuk, 
Sowinska-Przepiera, and Friebe 2003).  
Bone is connective tissue, meaning the majority of its makeup is extracellular 
matrix with the minority of the tissue being cells. As previously stated, bone matrix is 
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comprised of both an organic phase that is mainly type I collagen and a mineral phase 
composed of hydroxyapatite (Ca10(PO4)6(OH)2) (Boskey 2013), making bone matrix an 
intricate, composite material. The amount and arrangement of both components of bone 
matrix determine the characteristics of bone. The properties of bone can be divided in to 
factors that determine bone quantity and factors that determine bone quality. Bone 
quantity factors include composition by mass of both the mineral and organic component, 
while bone quality factors include mineralization properties of hydroxyapatite, such as 
crystallite size, perfection and orientation, collagen content, crosslinking, and 
microarchitecture. Weakness of bones is usually attributed to irregularities in one or more 
of these factors. Deficits in the mineral component usually result in decreased stiffness, 
which is linearly related to the amount of force and therefore a more straightforward 
measure of strength, and defects in the organic matrix component result in problems with 
resistance to tensile strength and torque, and abnormal ductility (Saito and Marumo 
2015). Weak bone leads to skeletal fragility and an increased susceptibility to fracture 
(Boskey 2013). While decreased bone mineral density, which can be measured using 
non-invasive DXA scans, is clinically considered the hallmark of measuring 
susceptibility to fracture in various pathological bone diseases, it is oftentimes not 
correlated directly with decreases in bone strength (Saito and Marumo 2015). This is 
because of the importance of the organic collagen framework in determining bone 
quantity and quality. Both decreased collagen content and organization can affect the 
mechanical properties of bone leading to increased fracture. This is evident in diseases 
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such as Osteogenesis Imperfecta, where mutations that affect both the quantity and/or 
quality of collagen lead to severe skeletal irregularities (van Dijk et al. 2011).  
II. Collagen, Lysyl Oxidase, and Bone 
Collagen is the major structural protein of the human body, making up 25% of the 
whole body protein content. It is the primary component of the extracellular matrix, and 
is therefore indispensable in connective tissue and is very important for the epithelium as 
well. Collagen provides strength and support to tissues in the human body due to its 
ability to connect various components of the extracellular matrix and to withstand 
mechanical forces encountered by connective tissue. Collagen is also involved in cell 
signaling, providing information about the extracellular environment to the intracellular 
environment of cells (Shoulders and Raines 2009). There are 28 types of collagen, 
however 80-90% is of type I, II, and III with type I being the most abundant in the human 
body. Type I collagen is a made up of products from three alpha-polypeptide genes: 2 
Col1α1 and 1 Col1α2 gene products. These collagen protein products are very rich in 
proline and glycine, which help in the formation of a strong, triple stranded super-helix 
(Shoulders and Raines 2009). During collagen synthesis in the endoplasmic reticulum, 
procollagen chains undergo proline and lysine hydroxylation by prolyl and lysyl 
hydroxylase, respectively (Kivirikko and Pihlajaniemi 1998). Hydroxylation of specific 
lysine residues determines future cross-link formation and plays a role in the 
biomechanical properties of bone, as evidenced by the bone phenotype in Ehlers-Danlos 
syndrome, a disease caused by a mutation in lysyl hydroxylase (Walker et al. 2005). 
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After these and other proline and lysine modifications, each procollagen alpha chain 
combines with two others to form a hydrogen-bonded triple stranded helix and is secreted 
in to the extracellular environment. Type I collagen is the most abundant (95%) protein 
found in the bone organic matrix and is synthesized by osteoblasts during bone formation 
(Boskey 2013). When creating new bone it is critical for osteoblasts to first create an 
organic matrix that provides a framework for mineralization by providing a scaffold for 
cells and directing hydroxyapatite crystal formation in to the correct orientation (Tomoaia 
and Pasca 2015). If bone cells and their associated factors do not carry out this initial step 
correctly, the bone will not form properly even if sufficient mineral is being produced. 
Once collagen is in the extracellular space, it undergoes additional 
posttranslational modifications that lead to the eventual formation of mature, insoluble 
collagen. Type I collagen is composed of two non-helical regions, called telopeptides, at 
the N and C terminus of each polypeptide chain, with a center helical region. 
Stabilization of newly formed collagen is achieved by the formation of covalent cross-
links between the helical and non-helical domains of adjacent collagen molecules. The 
extent of collagen cross-linking determines the strength of the collagenous matrix, 
conferring important mechanical properties to connective tissue. There are two major 
types of collagen cross-links: enzymatic cross-links and non-enzymatic glycation or 
oxidation-induced AGEs cross-links (AGE= advanced glycation endproduct) (Saito and 
Marumo 2015). Enzymatic cross-linking in collagen requires enzymes from the lysyl 
oxidase (LOX) family. Lysyl oxidases are copper dependent amine oxidases that 
oxidatively deaminate the epsilon amino group of peptidyl lysine and hydroxylysine 
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residues of collagen to form reactive peptidyl aldehydes. These aldehydes react 
spontaneously with either other deaminated or unmodified lysines and hydroxylysines on 
a neighboring collagen chain or molecule to form a variety of intermolecular cross-links 
between collagen molecules (Csiszar 2001).  
There are four isoforms of LOX that have the same catalytic site and therefore the 
same enzymatic activity: LOXL1, LOXL2, LOXL3, and LOXL4. The C-terminal 
domains of LOX and its family members have conserved sequence, and contain the 
catalytic activity of the enzyme. LOX and LOXL1 are the most closely related in 
structure, both containing a pro-region that is post-translationally processed, and both 
lacking the scavenger receptor cysteine rich domain present in LOXL2-LOXL4 (Liu et 
al. 2007). LOX and LOXL1 are both synthesized as pro-proteins with an N-glycosylated 
N-terminal pro-peptide. Following secretion of proLOX and proLOXL1 into the 
extracellular space, the N-terminal peptide is proteolytically cleaved and is referred to as 
LOX and LOXL1 propeptide (Trackman et al. 1992). Functions of LOX propeptide 
(LOX-PP) have been described in the literature (Grimsby et al. 2010; Vora, Guo, et al. 
2010), however LOXL1 propeptide, unlike LOX-PP, is unlikely to be intact after its 
release due to multiple proteolytic processing events (Trackman 2018). The cleavage of 
LOX and LOXL1 propeptide is performed by procollagen-C-proteinases, and results in 
the generation of a fully active, mature LOX and LOXL1 enzyme (Panchenko et al. 
1996).  
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Lysyl oxidase derived cross-links can further be divided into immature and 
mature cross-links. There are two types of immature cross-links: hydroxylysine aldehyde 
derived cross-links and lysine aldehyde derived cross-links. Hydroxylysine aldehyde 
derived cross-links, also known as ketoimines, are formed from the condensation of 
telopeptide aldehydes with a hydroxylysine in the helical region of a neighboring 
collagen molecule. These cross-links can be further stabilized by reduction of the 
resultant Schiff base with sodium borohydride to form dihydroxy-lysinonorleucine 
(DHLNL) for subsequent identification. The second type of immature cross-links are the 
lysine aldehyde derived cross-links, also known as aldimines. A common example of this 
type of cross-link is dehydrolysinonorleucine (deH-LNL), which is formed from the 
condensation of a telopeptide lysine aldehyde with a helical lysine aldehyde and can be 
further reduced to hydroxylysinonorleucine (HLNL). Mature cross-links are trivalent and 
thus more stable than their divalent, immature counterparts. There are at least three 
trivalent cross-links: hydroxylysyl pyridinoline (HL-Pyr), made from two hydroxylysyl 
aldehydes and a helical unmodified hydroxylysine, lysyl-pyrindoline (L-pyr), made from 
two hydroxylysine aldehydes and an unmodified lysine residue, and pyrrole, a 
trifunctional maturation of ketoimines (Knott and Bailey 1998). These stable trivalent 
cross-links constitute the majority of cross-links in normal, healthy bone (Saito and 
Marumo 2015). 
The extent and type of cross-linking in bone determines its material properties. 
Increases in non-enzymatic cross-linking and decreased enzymatic cross-linking are 
involved in the pathology of a myriad of bone diseases, making lysyl oxidase itself an 
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essential determinant in the maintenance of bone integrity. The importance of lysyl 
oxidase in bone was first discovered in Greece, Asia and Africa in people who consumed 
sweet peas, which is a famine crop in these countries. The consumption of sweet peas 
results in a disease of connective tissue called lathyrism. This condition is characterized 
by a variety of connective tissue abnormalities, including gross skeletal deformities and 
increased fracture risk, referred to as osteolathryism. β-aminopropionitrile or BAPN, was 
the molecule isolated from sweet peas that was responsible for this disease. It is a specific 
and potent pan LOX inhibitor. When the collagen was examined in these bones, it was 
abnormally soluble and immature (Barrow, Simpson, and Miller 1974). BAPN is now a 
commonly used substrate in the lab to study lysyl oxidase, and inhibition by low 
concentrations of BAPN distinguishes lysyl oxidases from other more common amine 
oxidase enzymes (Kagan and Trackman 1991). In a paper by Paschalis et al., it was 
shown treatment of mice with BAPN results in significantly reduced bone volume, 
quality, and mechanical properties without affecting the mineral component (Paschalis et 
al. 2011). Furthermore, in a paper by McNerny et al, it was shown that BAPN treatment 
in mice alters the crosslink profile in bone, which correlates with a reduction in the 
material property of toughness, which is the ability of a material to absorb energy and 
plastically deform without fracturing, and property conferred to bone by the organic 
matrix (McNerny et al. 2015). Therefore, a reduction in lysyl oxidase activity can 
negatively affect bone strength independently of changes in mineral properties which, as 
previously stated, mainly affect stiffness. While stiffness is important for skeletal support, 
an ability to resist fracture requires both stiffness and toughness (Paschalis et al. 2011). 
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Currently, clinical tests used to diagnose and evaluate treatment success in diseases of the 
bone in human patients focus on analyzing the mineral component. However, the lack of 
a proper tests to analyze the collagen profiles of bone as an accurate predictor for fracture 
risk may explain the difficulty of proper therapeutic intervention for certain bone 
diseases.  
Osteoblasts produce lysyl oxidases during the process of bone formation. 
However, the expression profiles of LOX and LOXL1-LOXL4 are highly distinct and 
change as a function of cell differentiation and matrix mineralization, suggesting they 
each have distinct roles in osteoblast development. Osteoblasts undergo well 
characterized genetic and phenotypic changes as they begin to differentiate and produce 
matrix. Collagen synthesis occurs maximally during the proliferative phase of the 
osteoblast and decreases during the matrix deposition phase, at which time collagen is 
actually deposited (Gerstenfeld et al. 2003). LOX and LOXL1 are the most abundantly 
expressed LOX isoforms in osteoblasts, and are at their maximum expression and activity 
level during the matrix deposition phase (Pischon et al. 2009), indicating lysyl oxidases 
play a key role in regulation of the extracellular assembly of collagen. Our lab has also 
shown that LOX plays a role in bone formation outside of its enzymatic cross-linking 
capabilities. In a paper by Khosravi et al., inhibition of LOX was shown to have negative 
effects on the proliferation of a pluripotent mesenchymal progenitor cell line, a cell line 
that is able to differentiate in to osteoblasts but one that does not produce any appreciable 
amount of matrix. Interestingly, when LOX was knocked down in these progenitor cells 
using two different shRNA constructs, there was a significant reduction in their 
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proliferation. Extensive progenitor cell proliferation is needed during bone formation to 
produce a sufficient pool of precursor cells that can later differentiate in to the large 
number of osteoblasts needed during periods of bone formation (Khosravi, Sodek, Xu, et 
al. 2014). LOX has been shown to have non-crosslinking related effects on other cell 
lines as well (Lucero, Maki, and Kagan 2011; Perryman and Erler 2014), therefore this 
finding could have additional biological implications in bone and other tissues.  
III. Bone Diseases: Osteoporosis 
Osteoporosis is a skeletal disorder characterized by compromised bone strength 
predisposing individuals to an increase in risk fracture. Osteoporosis occurs in both men 
and women as a function of aging but, as previously stated, is accelerated in women due 
to post-menopausal loss of estrogen, which is osteoprotective (Simon 2007). In women 
aged 50-59 the risk of osteoporotic fracture is only about 4%, but rises to 52% after 65 
years of age resulting from a drastic change in bone quantity and quality. There is a 
temporal effect on the site of fracture in women suffering from osteoporosis. The first 
fractures occur in the vertebrae and normally manifest as microfractures which then 
devolve in to more severe fractures with increases in age. This is followed by hip 
fractures that occur with increased prevalence at around 75 years of age (Burr 2002). By 
histomorphometric analysis, it is the trabecular bone that is most severely affected in 
post-menopausal osteoporosis. Trabecular bone is located on the inside of the bone and is 
less dense than the outside shell of the bone, referred to as cortical bone. While cortical 
bone endows bone with stiffness, the trabecular bone is needed for toughness, which as 
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stated previously, is the ability of a material to deform in response to force without 
fracturing. Trabecular bone is a porous network comprised of units called trabecula, 
which create lattice like structures, rods and plates, and account for the high surface area 
to volume ratio of trabecular bone. In osteoporosis, there is a decrease in the number and 
size of these trabecula, as well as a decrease in connective density and subsequent 
increase in porosity of the lattice-like network (Bouxsein et al. 2005). 
Therapies for osteoporosis currently fall in to two categories: anabolic reagents, 
such as PTH analogues, and anti-resorptive agents, such as estrogen and bisphosphonates. 
Both types of treatments either increase or maintain BMD and decrease fracture 
incidence. However these therapies do not factor in defects that occur in the organic 
matrix as a result of aging. As bone ages, the organic matrix to mineral ratio decreases 
significantly and overall matrix heterogeneity decreases, which could have implications 
for bone quality in patients with age-related osteoporosis (Boskey 2013). Furthermore, 
the anti-resorptive therapies used for osteoporosis lead to the retention of old bone 
because they decrease bone resorption. This older bone has increased collagen maturity 
and increased non-enzymatic cross-links (Oxlund, Mosekilde, and Ortoft 1996). Non-
enzymatic cross-linking, the AGEs mentioned previously, disrupts the normal collagen 
fibril arrangement in the organic matrix framework, resulting in bone that is weaker 
(Saito et al. 2006). Therefore these anti-resorptive therapies, especially when they are 
coupled with agents that increase the amount of mineral, are analogous to putting more 
concrete on a bridge whose foundation is cracked, and could explain why the treatments 
for osteoporosis only modestly decrease fracture rate.  
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IV. Bone Diseases: Diabetic Osteopenia 
Diabetes is a group of metabolic disorders characterized by hyperglycemia, which 
is elevated blood glucose resulting from a shift from normal to impaired glucose 
tolerance. Diabetes is further classified into two types depending on the events that lead 
to hyperglycemia. Hyperglycemia in type I diabetes is caused by a CD4+ and CD8+ T-cell 
mediated autoimmune response that leads to the destruction of the insulin producing 
pancreatic β-cells, resulting in reduced insulin secretion and impaired glucose tolerance. 
In type II diabetes, there is a decreased cellular response to insulin, referred to as insulin 
resistance, which is related to diet and is often concurrent with obesity (Shaw, Sicree, and 
Zimmet 2009; Ship 2003). The national diabetes statistics report from the CDC in 2017 
states that more than 100 million U.S. adults are now living with diabetes, and it was 
reported as the seventh leading cause of death in the U.S. in 2015 (National Diabetes 
Statistics Report 2017).  
Complications arising after the onset of hyperglycemia, otherwise known as 
secondary diabetes complications, are now well understood to be increasingly prevalent 
public health problems. Diabetes causes chronic issues in nearly every tissue in the 
human body, with extensive complications occurring in organs that are highly 
vascularized, such as the eye, brain, kidneys, and heart. Macrovascular complications 
include coronary artery disease and stroke, and are the main causes of morbidity in 
diabetes. Microvascular complications include diabetic retinopathy, the leading cause of 
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blindness in the U.S., and diabetic neuropathy (Chawla, Chawla, and Jaggi 2016). 
Recently more attention has been placed on non-vascular abnormalities associated with 
diabetes, one of which is bone fragility and increased susceptibility to osteoporotic 
fractures referred to as diabetic osteopenia. Decreased bone health in diabetes is not only 
a debilitating health problem in and of itself, but decreased mobility due to increased 
fracture risk can exacerbate the macrovascular complications that are usually the cause of 
death in diabetes (McCabe, Zhang, and Raehtz 2011). The mechanisms of diabetic bone 
loss are not well understood, especially in type II diabetes where increased fracture risk is 
controversial and oftentimes accompanied by increases in BMD (Karsenty 2006; 
McCabe, Zhang, and Raehtz 2011). This is most likely due to increased bone formation 
as a result of mechanical loading, a consequence of obesity in type II diabetic patients 
(Cao 2011). Diabetic bone loss in type I diabetes however is clearly associated with a low 
bone formation osteopenia, and has therefore become the hallmark disease model for 
studying diabetic bone complications. Bone loss in type I diabetes is particularly severe 
compared to other metabolic bone diseases, with more than 50% of total patients and 
20% of patients aged 20-56 meeting the criteria for being osteoporotic (McCabe 2007; 
Kemink et al. 2000).  
Diabetic osteopenia is a very different disease from age-related and post-
menopausal osteoporosis. While post-menopausal osteoporosis is caused by an 
exacerbation of bone resorption due to increased osteoclast number and activity, analysis 
of serum markers in diabetic humans suggests bone resorption remains unaltered. There 
is, however, a significant decrease in serum levels of the osteoblast specific marker 
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osteocalcin, a commonly used index for measuring bone formation (Kemink et al. 2000; 
McCabe 2007). In type I diabetic mouse models, bone loss is even more drastic with 
similar decreases in serum osteocalcin levels that are unaccompanied by changes in bone 
resorption markers. Histological analysis of bone sections from diabetic mice stained for 
osteocalcin and TRAP (an enzyme produced specifically by osteoclasts) show decreased 
osteoblast number and unchanged osteoclast number, corroborating the changes seen in 
serum from diabetic mice and humans (Botolin and McCabe 2007; Verhaeghe et al. 
1990). More recent studies have shown that diabetes diminishes the differentiation of the 
osteoblast progenitor cell mesenchymal stromal cells, or redirects the differentiation of 
these cells towards the adipogenic lineage (Kalaitzoglou et al. 2016). Taken together 
these studies suggest a low bone formation cause for bone fragility in diabetes, which is 
different from the pathology of osteoporosis, emphasizing the importance of the 
condition-specific study of diabetic bone disease. 
Fracture incidence in type I diabetes is much more pronounced than can be 
explained by a decrease in mineralization. Measures of reductions in BMD used to 
diagnose and treat diabetic osteopenia do not correlate well with the impairment in 
mechanical properties seen in diabetic bone (Vestergaard 2007). This indicates that there 
is a defect in the organic matrix of bone that can explain why bone fractures more easily 
in individuals with diabetes. Previous studies have reported that in various mouse models 
for diabetes, there is an abnormal arrangement of collagen fibrils that results in a 
significant reduction in bone material properties without affecting the mineral component 
of bone (Saito et al. 2006; Tomasek et al. 1994). Results from these studies suggest that 
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these collagen defects are caused by either accumulation of non-enzymatic AGE cross-
links or the reduction of lysyl oxidase mediated enzymatic cross-linking (Saito and 
Marumo 2015; Saito et al. 2006). However, the expression levels of the enzymatic cross-
linking enzyme lysyl oxidase and its isoforms have not been examined in diabetic bone.  
V. Incretins: Glucose-Dependent Insulinotropic Peptide (GIP) 
In 1902, a study was done by Moore et al. showing administration of gut extracts 
to diabetic patients lowered levels of sugar in their urine, presumably through stimulation 
of the pancreas. In 1929, these glucose lowering elements were isolated and named 
incretins (an abbreviation for intestinal secretion). In the 1960s, it was discovered that 
oral glucose administration resulted in a much more profound increase in insulin 
secretion than intravenous delivery of glucose, which is now known as the “incretin 
effect”(Creutzfeldt 2005). Upon the ingestion of glucose, the intestine secretes these gut 
hormones that travel through the bloodstream and stimulate insulin secretion from 
pancreatic β-cells, accounting for 50-70% of insulin secretion and glucose control 
following a mixed meal. Only two gut hormones are able to act as incretins. The first to 
be characterized is referred to as glucose-dependent insulinotropic peptide or GIP. GIP is 
a 42 amino acid peptide that belongs to a family of structurally related hormones that 
include secretin and glucagon. It is secreted from intestinal K-cells, most of which are 
located in the distal duodenum, with smaller amounts found throughout the entire small 
intestine (Drucker 2006). Now it is known that in healthy individuals GIP acts directly on 
pancreatic β-cell islets to stimulate insulin secretion, resulting in the prompt uptake of 
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glucose into various peripheral tissues. This only occurs if plasma blood levels of glucose 
are increasing, as evidenced by studies showing administration of oral fat or protein alone 
does not induce GIP-stimulated increases in insulin secretion, thus the name glucose 
dependent insulinotropic peptide (Kim and Egan 2008). Another gut hormone named 
glucagon-like peptide 1 (GLP-1) was later discovered to exert similar glucose dependent 
effects on insulin secretion (Drucker 2006). GLP-1 is derived from the proteolytic 
processing of pro-glucagon, while GIP is encoded by the gip gene and is processed to a 
42 amino acid hormone from proGIP, a larger 153 amino acid prohormone precursor 
(Drucker 2006). 
The human GIP receptor (GIPR) belongs to the 7-transmembrane spanning 
heterotrimeric G-protein coupled receptor family, and is expressed in pancreatic β-cell 
islets and in adipose tissue, as well as in the heart, brain, and bone (Drucker 2006). GIP 
exerts its effects by binding to its receptor, releasing Gαs stimulatory G-proteins from 
GIPR that activate adenylyl cyclase, causing a rise in intracellular cAMP levels. This 
results in insulin secretion in pancreatic β cells via a protein kinase A (PKA) dependent 
mechanism, whereby activation of PKA by cAMP results in altered ion channel activity 
and enhanced exocytosis of insulin-containing granules (Seino, Fukushima, and Yabe 
2010). Other signaling pathways are activated by increased cytosolic cAMP as well, 
including the PI3K and phospholipase A2 pathway, all of which contribute to pancreatic 
β-cell depolarization and insulin secretion (Kim and Egan 2008). For many years it was 
thought that the main function of GIP was to stimulate insulin secretion. However in 
recent years, studies have shown that GIP signaling can also cause activation of the MAP 
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kinase pathway in pancreatic β-cells, resulting in enhanced β-cell proliferation. This was 
the first indication that GIP has non-insulinotropic functions that could be of 
physiological relevance (Kim and Egan 2008).  
VI. GIP in Bone and Diabetes 
Receptors for GIP are expressed on both osteoblasts and osteocytes, and just like 
in the pancreas, GIP signaling has proliferative and anabolic effects in bone. GIP 
signaling in bone causes an increase in both alkaline phosphatase activity and collagen 
synthesis in osteoblasts, indicating GIP is involved in the maintenance of both the organic 
and inorganic matrix (Bollag et al. 2000). While these are the only metabolic functions 
for GIP in bone that have been described in the literature, studies done on transgenic 
mouse models emphasize the importance of GIP in bone metabolism. In GIP 
overexpressing transgenic mice, there is significant enhancement of bone formation and 
subsequent increases in bone mass concurrent with increased bone strength (Xie et al. 
2007). In GIPR -/- knockout mice, there is a significant decrease in measures of bone 
formation, such as mineral apposition rate and bone formation rate, as well as profound 
deficits in trabecular bone structure including decreases in trabecular bone volume and 
thinned trabeculae (Tsukiyama et al. 2006). In a study by Gaudin-Ardin et al. it was 
shown that, in addition to decreased bone formation, there was a significant change in the 
crosslinking profiles in GIPR -/- mice that correlated with reduced mechanical properties 
in the long bones (Gaudin-Audrain et al. 2013), suggesting that GIP is somehow needed 
to maintain the integrity of the collagen framework in bone. In a paper by Miecowska et 
  
  
19 
al., it was shown that GIP can augment LOX activity in osteoblasts, resulting in an 
increase in collagen crosslinking (Mieczkowska et al. 2015). However these studies were 
all done in vitro and the effect of this increase in LOX on bone properties was not 
examined. Importantly, in the studies on GIPR -/- mice there were no changes in 
osteoclast number or activity (Tsukiyama et al. 2006). This observation, combined with 
the collagen matrix deficits, provides evidence that the bone phenotype in GIPR -/- is 
very similar to that seen in the low bone turnover osteopenia in diabetes. 
Nutrient-stimulated insulin secretion is decreased in diabetic patients, prompting 
researchers to investigate if diabetes affects incretin secretion or function. Interestingly, 
serum GIP levels are normal in type I diabetics, and are either normal or slightly 
increased in type II diabetics (Kim and Egan 2008). However, a 1993 study by Nauck et 
al. demonstrated that GIP administration, even at higher than normal physiological doses, 
had little effect on insulin secretion in diabetic humans (Nauck et al. 1993). This is 
secondary to the development of diabetes, as evidenced by the loss of the incretin effect 
in patients with chronic pancreatitis only after the onset of diabetes, and in the loss of the 
incretin effect in gestational diabetes (Holst et al. 2011). Desensitization to GIP in the 
pancreas has been corroborated in mouse models as well, but the molecular mechanisms 
for this decreased GIP responsiveness in diabetes is still largely unknown (Seino, 
Fukushima, and Yabe 2010).  
 
VII. Anti-Incretins 
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In 1995, Pories et al. published results from a 10 year follow up study showing 
that bariatric surgery, a surgical treatment for obesity, resulted in a reversal of 
hyperglycemia in 83% of diabetic patients, as well as a restoration of insulin secretion 
from pancreatic β-cells (Pories et al. 1995). Although decreased fat mass due to weight 
loss is known to improve sensitivity to insulin in type II diabetic patients, this effect was 
seen even in patients who did not lose significant amounts of weight (Pories et al. 1995), 
suggesting the existence of other mechanisms to account for this phenomenon. Many of 
the common types of bariatric surgery, including gastric bypass surgery and sleeve 
gastrectomy, involve a duodenal jejunal bypass, which restricts nutrient access to the 
proximal small intestine by redirecting the stomach outlet to the distal intestine. This lead 
clinical researchers to posit two hypotheses for the recovery of normoglycemia in 
diabetic patients after bariatric surgery. The first, the hindgut hypothesis, suggests that 
enhanced delivery of nutrients to the distal small intestine results in increased secretion of 
incretins, and therefore increased glucose dependent insulin secretion. In contrast but not 
necessarily mutually exclusive, the second hypothesis, the foregut hypothesis, postulates 
that bypassing the upper small intestine restricts nutrient induced secretion of upper 
gastrointestinal factors that normally defend against hypoglycemia by reducing insulin 
secretion (Salinari et al. 2017; Chaudhry et al. 2016).  
In 1997, it was discovered that the main source of dopamine in the human body is 
derived from the gut, while brain derived dopamine only accounts for a small percentage 
(Eisenhofer et al. 1997). Gut derived dopamine is the same molecule as the dopamine 
neurotransmitter in the brain, but instead is produced in the stomach and upper small 
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intestine and acts like a hormone, traveling through the bloodstream to bind to its various 
targets through the body, and does not cross the blood-brain barrier. Studies on the 
functions of gut-derived dopamine are limited, however a series of recent, innovative 
studies by Maffei et al. revealed that increases in peripheral dopamine production are a 
function of serum GIP levels as well as insulin secretion. Upon a standard mixed meal 
challenge in rats, increases in GIP occur almost immediately after nutrient consumption, 
followed by an excursion of insulin secretion at about 30 minutes. Interestingly, shortly 
after this spike in serum insulin, there is a spike in levels of serum dopamine concurrent 
with a rapid reduction in both GIP and insulin levels (Maffei et al. 2015). This suggests 
the existence of a gut based mechanism for homeostatic glucose control, and provided the 
first evidence that dopamine could represent an “anti-incretin” capable of antagonizing 
incretin effects in the pancreas. A study by Rubi et al. in 2005 showed that pancreatic β-
cells express dopamine receptors of the D2R subtype, which are Gαi/o coupled inhibitory 
receptors, and that D2R agonists were able to inhibit insulin secretion in human 
pancreatic β-cells (Rubi et al. 2005). Maffei et al. extended on this study by showing that 
treatment of pancreatic β-cells with physiological concentrations of dopamine 
antagonized GIP stimulated increases in cytosolic cAMP and subsequent insulin secretion 
(Maffei et al. 2015). Taken together with the fact that bariatric surgery bypasses the 
stomach and upper small intestine where dopamine is produced, it reasonable to conclude 
that dopamine acts as an anti-incretin to prevent hypoglycemia in healthy individuals, and 
that this inhibitory circuit is somehow dysregulated in diabetes. Interestingly, expression 
of GIP in RNA extracted from whole-blood samples taken from diabetic patients who 
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had resolved hyperglycemia as a result of gastric bypass surgery was shown to be over 
four times that of diabetic control patients (Moran-Atkin et al. 2013).  
The concept that dopamine can have an effect on diabetes has also been supported 
by studies done on patients taking anti-psychotic drugs for the treatment of 
schizophrenia, which is caused by an increase in dopamine signaling in the brain. 
Amisulpride, an atypical anti-psychotic belonging to the benzamide structural class, is a 
drug approved for use in Europe for the treatment of schizophrenia due to its potent 
inhibition of D2/D3 receptors. A number of studies have suggested that patients taking 
amisulpride have a lower risk of developing type II and gestational diabetes. In a study 
done by Roix et al., it was shown that administration of amisulpride to diabetic mice 
improved insulin secretion and lowered blood glucose levels (Roix et al. 2012).  
OBJECTIVE 
Lysyl oxidases are essential for maintaining proper bone health, as evidenced by 
the disease osteolathryism that results from lysyl oxidase inhibition (Barrow, Simpson, 
and Miller 1974). The bone fragility and increased fracture risk seen in diabetic 
osteopenia far exceeds what can be explained by a decrease in bone mineral density 
(Vestergaard 2007). This discrepancy has not been addressed in clinical settings for 
studying diabetic osteopenia in humans or in therapeutic development efforts for diabetic 
bone disease. A recent paper by Xiao et al. is the first to directly show that it is the matrix 
phase that is deficient in diabetic bone. Analysis using a three-point bending test revealed 
that loss of mechanical behavioral properties in diabetic rats was mainly restricted to the 
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post-yield phase (Xiao et al. 2018). The pre-yield phase in mechanical testing is a 
measure of the strength of the mineral properties of bone, i.e. the force that is examined is 
stiffness that is conferred mainly by the amount of hydroxyapatite. However the post-
yield phase measures the resistance to strain since it measures the extent to which bone 
can be displaced with increasing force until the point of fracture. This measures the 
properties conferred to bone by the collagen matrix, which allows bone to respond to 
torsion, torque, and other heterogenic forces encountered in the daily life of the human 
skeleton (Saito and Marumo 2015). These results were supported by micro-computed 
tomography (micro-CT) analysis of the fracture surface, in which a flatter fracture 
surface was observed in the diabetic group while the control group showed a rough and 
twisted fracture surface. This indicates that diabetic bone is very stiff and rigid upon 
fracture due to its inability to adequately resist different kinds of forces, an ability present 
in bones containing a healthy collagen framework (Xiao et al. 2018). This mechanical 
bone defect in diabetes could explain the increased fracture risk seen in diabetic patients. 
While previous studies have shown that there is abnormal collagen crosslinking due to 
non-enzymatic AGE formation in diabetes, and that there is decreased total biosynthetic 
cross-linking in diabetes in general (Saito and Marumo 2015; Saito et al. 2006), the cause 
of the inhibition of lysyl oxidase activity in diabetes has not been examined.  
The crosstalk between gastric hormones and bone regulation is increasingly being 
recognized as an important contributor to a healthy bone metabolism. It is now 
appreciated that GIP is a direct contributor to bone anabolism upon its release from 
intestinal K-cells in response to nutrient consumption (Xie et al. 2007; Tsukiyama et al. 
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2006). It does not just contribute to bone metabolism indirectly through its effects on 
insulin secretion, it binds to GIP receptors that are expressed on osteoblasts and causes an 
increase in cAMP production, indicating it directly causes an increase in intracellular 
signaling in bone forming cells (Mieczkowska et al. 2015). However, the downstream 
effectors in this signaling cascade are not known. A previous study by Miecowska et al. 
has shown that GIP treated osteoblasts have increased mature collagen crosslinks and a 
BAPN assay has shown an increase in lysyl oxidase activity (Mieczkowska et al. 2015), 
but direct increases in lysyl oxidase mRNA and intracellular and secreted LOX protein 
have not been shown.  
Incretins account for 60-70% of glucose stimulated insulin secretion (Drucker 
2006), making them an important contributor to a normal glucose tolerance. In diabetes, 
pancreatic β-cells are still able to respond to some extent to the other incretin GLP-1, but 
not GIP, making GLP-1 an attractive therapeutic for diabetes and leaving GIP to become 
known as the “forgotten incretin” (Kim and Egan 2008). However GIP, not GLP-1, has a 
direct effect on bone (Bollag et al. 2000), and the inability of pancreatic β-cells to 
respond to GIP in diabetes could be relevant to diabetic osteopenia if osteoblasts are 
experiencing a similar problem.  
The development of the anti-incretin hypothesis and the discovery that gut-
derived dopamine inhibits insulin secretion in pancreatic β-cells by antagonizing GIP and 
GLP-1 mediated signaling is also relevant to diabetic bone complications (Maffei et al. 
2015). The effect of dopamine on bone has been previously studied, but only in the 
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context of dopamine as a neurotransmitter and the relationship between the nervous 
system and bone, which is also important since bone is innervated by both sympathetic 
and sensory nerves (Lee et al. 2015; Hanami et al. 2013). However, most dopamine is 
produced in the periphery whereas only a minor fraction is synthesized in the brain, and 
dopamine cannot pass the blood-brain barrier (Eisenhofer et al. 1997). Importantly, 
studies on gut-derived versus brain derived serotonin (another neurotransmitter/gut 
hormone) have shown that even though two different sites are producing the same 
molecule, the effects can be quite different on bone. When produced peripherally, 
serotonin acts as a hormone to inhibit bone formation. In contrast, when produced in the 
brain, serotonin acts as a neurotransmitter to exert a positive effect on bone by enhancing 
bone formation and limiting bone resorption (Ducy and Karsenty 2010). In other words, 
serotonin central and peripheral functions are completely dissociated in bone. Peripheral, 
gut-derived dopamine and its effects on bone have yet to be studied, and in the context of 
diabetic osteopenia this relationship could be highly relevant. 
The present study seeks to first investigate the skeletal phenotype in mice 
genetically deficient in the LOXL1 isoform, and determine whether any phenotype found 
could resemble bone pathologies such as those seen in osteoporosis or diabetic 
osteopenia. Since LOX-/- mice are neonatal lethal due to cardiovascular abnormalities 
(Hornstra et al. 2003), the LOXL1 isoform was initially chosen to study the effects of 
lysyl oxidases on bone because its structure is the most similar of the four other isoforms 
to LOX, and because LOX and LOXL1 are expressed by osteoblasts (Pischon et al. 
2009). Bones were evaluated using micro-CT and histomorphometric analyses, as well as 
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enzyme-linked immunosorbent assays (ELISAs) for common cytokines involved in bone 
regulation. Based on these results, which showed a sex-specific bone phenotype more 
resembling osteoporosis, we decided to develop different methods to study diabetic 
osteopenia. We first characterized LOX +/- mice and low dose streptozotocin-induced 
diabetic mice using the same methods above to see if the LOX haploinsufficient mice 
could resemble the low bone formation osteopenia seen in our diabetic mouse model, 
which is a model for type I diabetes. We then sought to examine the specific mechanism 
for diabetic osteopenia, and hypothesized based on the previously stated studies that 
diabetes interferes with GIP-stimulated upregulation of lysyl oxidase in osteoblasts. We 
also hypothesized that increased circulating gut-derived dopamine arising from peripheral 
tissues in diabetes may cause diabetic osteopenia by antagonizing the GIP signaling 
pathway in osteoblasts like it does in pancreatic β-cells, leading to decreased LOX 
production in osteoblasts and subsequent deficiencies in the organic matrix component of 
diabetic bone. We then attempted to ameliorate the diabetic bone phenotype in our 
diabetic mouse model by in vivo intraperitoneal (IP) administration of the drug 
amisulpride, a potent and specific dopamine receptor 2 inhibitor.  
MATERIALS AND METHODS 
 
 
Mouse Models and Tissues 
 
LOXL1-/- mice were generated in accordance with a previously published strategy 
employed for generating LOX null mice (Hornstra et al. 2003). The ATG codon of LOXL1 
and surrounding bases of a BAC clone containing LOXL1 were converted to NotI 
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restriction sites by site-directed mutagenesis (QuikChange mutagenesis, Stratagene, La 
Jolla, CA).  The NotI fragment of the modified gene including the PGK-Neo cassette was 
cloned into the NotI site of the mutagenized ATG initiation codon of the LoxL1 gene 
construct. This construct deletes the ATG initiation codon and replaces it with the PGK-
Neo cassette in the opposite transcriptional orientation. Correctly targeted RW4 embryonic 
stem cells (129/SvJ), carrying this mutation, were injected into C57BL/6 blastocysts and 
chimeric mice were produced. This mutation was transmitted into the germline and mice 
homozygous for this mutation (LOXL1-/-) were generated in a mixed 129/SvJ × C57BL/6 
background. Mice were identified as heterozygous or homozygous with respect to the 
targeted allele by PCR of tail tip DNA using nested primers (wild-type: 5’ 
TTGTTCTCCCACTGGATCAGCTGCC 3’; mutant: 5’ 
TACCGGTGGATGTGGAATGTGTGCGA 3’; common: 5’ 
TGGGAAGAGAAGCACGCA CCGAG 3’). LOXL1-/- mice (backcrossed into the 
C57BL/6 background for more than 7 generations) were bred at University of Texas 
Southwestern Medical Center. All tissues were harvested under the same specified 
conditions from knockout and wild type littermate controls at 13 weeks of age, and all 
procedures were approved by the respective IACUC committees at both Boston University 
and University of Texas Southwestern Medical Center.  
For studying diabetic osteopenia, eight week old male and female wild type and 
LOX +/- littermate mice were also developed using the same methods as above (Hornstra 
et al. 2003). Briefly, BAC clones were obtained by hybridizing a 129/SvJ filter library 
(Genome Systems, St. Louis, MO) using a cDNA probe from the 3′-untranslated region of 
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the Lox gene. The mutation for the modified start codon of the Lox gene was transmitted 
into the germline and mice heterozygous for this mutation (LOX+/−) were generated in the 
same mixed 129/SvJ × C57BL/6 background. These mice, unlike LOX -/- mice, are viable, 
making them a useful alternative model to LOX -/- mice for studying the role of LOX in 
bone. Wild type C57BL/6 male and female mice (Jackson Laboratory) were also purchased 
for experiments not involving LOX +/- animals. 
A subset of male and female LOX +/- and wild type mice were then made diabetic 
by multiple low dose streptozotocin (STZ)-induction (Wu and Huan 2008a). This was 
achieved by intraperitoneal injections to mice at 40 mg/kg doses of streptozotocin (Sigma 
Aldrich catalogue #s0130) for five consecutive days. STZ is an antibiotic that destroys 
pancreatic β-cells, thereby inducing diabetes, making it a model for type I diabetes (Motyl 
and McCabe 2009b). STZ powder was dissolved in 0.1 M sodium citrate buffer solution 
pH 4.5. All mice became diabetic 12 days after STZ initiation, with two consecutive fasting 
blood glucose readings of >250 mg/dL. Control mice were injected with vehicle only 
(sodium citrate buffer) and maintained normal blood glucose levels. Blood glucose levels 
were monitored twice a week for an additional 8 weeks, which allows enough time for a 
diabetic bone phenotype to occur. Briefly, mouse tail veins were punctured using a 25 G 
needle to collect a drop of blood, which was used to measure blood glucose levels using 
Onetouch Ultramini blood glucose meter and corresponding blood glucose test strips. Mice 
were not administered insulin during this time.  
To study the effects of dopamine on diabetic osteopenia, a subset of wild type 
(Jackson Laboratory, C57BL/6) diabetic mice were administered the atypical anti-
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psychotic amisulpride for 4 weeks after the 8 week mark of diabetes. Ultra-pure 
amisulpride (Sigma aldrich catalogue #A2729) was first dissolved in cell culture grade 
DMSO, and then dissolved in ultra-pure PBS for a final concentration of 2% DMSO. Mice 
were injected intraperitoneally at the same time every day for 4 weeks at a dosage of 10 
mg/kg, which is a therapeutic dose used to treat schizophrenia in humans (Roix et al. 2012). 
Since amisulpride is an antipsychotic, behavior of the mice was monitored closely. 
After sacrifice, the left femur and spines were dissected and wrapped in PBS-
soaked gauze to be used for subsequent micro-computed tomography (μ-CT) analyses. The 
right femurs were fixed in 4% paraformaldehyde and then decalcified in 20% EDTA for 2 
weeks. Femurs were then processed for histology using paraffin embedded sectioning by 
the Center for Skeletal Research (P30 AR066261) histology core at Massachusetts General 
Hospital. The bones were embedded longitudinally with the intercondylar notch at the 
distal end facing upward.  
 
PHENOTYPIC CHARACTERIZATION 
 
Micro-Computed Tomography and Image Analysis 
 
All μCT analyses of femurs and L5 vertebrae were carried out at the µCT Imaging 
Core Facility at Boston University using a Scanco Medical µCT40 Scanning instrument 
(Brütisellen, Switzerland). The power, current, and integration time used for all scans were 
70 kVp, 113 μA, and 200 msec respectively. The femurs and spines were all scanned at a 
resolution of 12 microns/voxel. The software used for the subsequent contouring and 
analysis was developed by Scanco Medical. Regions selected for trabecular analysis were 
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the trabecular compartments of the distal metaphysis of the femur and the center of the 
vertebral body of the L5 vertebrae. For cortical analysis, the mid diaphysis of the femur 
and the cortical shell of the vertebrae were used for analysis (Bouxsein et al. 2010). To 
determine the trabecular region of interest of the femurs, the location of the growth plate 
was determined and the regions which were 60 microns removed from the end of the 
growth plate and which extended 1200 microns proximal of the growth plate were 
respectively analyzed. The entire lengths of the vertebrae were evaluated, comprising a 
total length of ~3600 microns. Gaussian filtering (sigma= 0.8, support=1) was used for 
partial background noise suppression. The threshold was set at a 16-bit gray value of 9830 
and this global threshold was applied to all of the samples (Gere and Goodno 2009). For 
contouring the perimeter of the trabecular region of the vertebrae, each transverse 2-D 
tomogram of the vertebra was manually traced to designate the cortical shell and trabecular 
regions. For separating the cortical and trabecular regions of the femurs, an automated 
method within the system software was used (Buie et al. 2007). Trabecular and cortical 
analyses were performed and reported as described (Bouxsein et al. 2010).  
 
LOXL1 and LOX Immunohistochemistry 
The primary antibody against LOXL1 was obtained from Abbiotec, catalogue 
#252215, and was generated against a unique human LOXL1-specific sequence conserved 
in mice. The anti-LOX antibody was obtained from Abcam (catalogue #ab31238) and is 
specific for the C-terminus portion of LOX conserved in humans and mice. Both antibodies 
were used at a dilution of 1:000 with an IgG control of the same concentration. For antigen 
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retrieval, slides were incubated in sodium citrate solution (pH6) and placed in a 37oC water 
bath for 1 hour and then incubated in 0.2% Triton-x100 solution in room temperature PBS 
for 20 minutes. Sections were blocked for non-specific staining using an avidin/biotin 
blocking kit (Vector laboratories) and positive staining was visualized using an HRP-
conjugated rabbit anti-mouse secondary antibody at a dilution of 1:2000 (Vector 
laboratories). Subsequent colorimetric development of peroxidase was performed using an 
ABC and DAB kit (Vector laboratories).  Slides were counterstained using hematoxylin. 
Sections were visualized using a Zeiss Axio Observer Z1 (Carl Zeiss Microscopy, Jena, 
Germany), and images captured using ZEN pro software (Carl Zeiss Microscopy, Jena, 
Germany). Three central sections were analyzed per animal. 
 
Osteoblast Density in the Distal Metaphysis 
 
Osteoblasts were visualized using an anti-osteocalcin antibody (Abcam catalogue 
#ab93876) and immunohistochemistry performed using the methods above. Osteoblasts 
were identified by positive staining and morphological criteria: cuboidal cells attached to 
the bone occurring in clusters, having an asymmetrically positioned nucleus, and 
counterstained light purple. The number of osteoblasts was normalized to millimeter of 
bone surface of the trabecular contour drawn using Image J software. The area analyzed 
was from the bottom of the growth plate extending 2 mm toward the opposite end of the 
long bone. All osteoblasts were counted in this area. Sections were visualized using a Zeiss 
Axio Observer Z1 (Carl Zeiss Microscopy, Jena, Germany), and images captured using 
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ZEN pro software (Carl Zeiss Microscopy, Jena, Germany). Three central sections were 
analyzed per animal. 
Osteoclast Density in the Distal Metaphysis 
 
Sections were stained for TRAP activity using TRAP stain composed of 1 mg/mL 
Fast Red Violet LB salt (Sigma Aldrich catalogue # F3381), and 2 mg/mL sodium tartrate. 
Cells were incubated in TRAP stain for 1 hour at 37oC.  The area analyzed was from the 
bottom of the growth plate extending 2 mm toward the opposite end of the long bone. All 
osteoclasts were counted in this area. Osteoclasts were identified as TRAP positive, 
multinucleated (3 or more nuclei) cells associated with the bone surface. Other identifiers 
included size (25-50 µM in diameter), and association with a resorption pit. Overlapping 
images were taken on an Olympus FSX100 and analyzed using FSX-BSW v02.02 software 
(Olympus America Inc., Center Valley, PA) which created a composite picture of the 
individual low magnification images (100X) taken of the area, as well as higher resolution 
images (200X). The number of osteoclasts was normalized to millimeter of bone surface of 
the trabecular contour drawn using Image J software.  
 
Growth Plate Analysis 
The chondrocyte density in the growth plate was calculated by counting the number 
of cells in each composite image and dividing by the total growth plate area as calculated by 
Image J software determined from hematoxylin and eosin stained sections. The average 
number of column forming chondrocytes was calculated by counting the number of cells per 
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column in 5 separate columns and averaging them. The average height of the growth plate 
was calculated by measuring the height at five different regions across the plate. 
 
Analysis of Collagen Organization  
 Collagen organization was analyzed using picrosirius red stained central sections as 
described (Junqueira, Bignolas, and Brentani 1979a). Picrosirius red stain was composed of 
0.5 g Sirius Red dye (Direct Red 80, Sigma Aldrich catalogue #43665) dissolved in 500 mL 
saturated aqueous picric acid. Sections were stained for 1 hour and counterstained with 
Weigert’s hematoxylin. Images were visualized using an Olympus IX70 microscope with 
and without polarizing filters engaged (Olympus Inc., Tokyo, Japan) and captured using 
Pictureframe software. The area analyzed for each image started at the center of the growth 
plate and extended ~ 2 mm down and to the right. Images were analyzed for blue, green, 
yellow, orange, and red birefringence. Images were taken at the same exposure and same 
orientation of the slide to ensure uniform birefringence.  
 
Serum Immunoassays 
Serum from wild type and LOXL1 mutant mice was tested for relative quantities of 
the following cytokines: IL-6, TNF-α, osteocalcin (OCN), osteoprotegerin (OPG), and 
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) via immunoassay using 
the Milliplex system (EMD Millipore, Billerica MA) according to the manufacturer’s 
instructions. This system utilizes mouse antibody-immobilized beads magnetized to a plate 
block. Serum samples were diluted 1:2 with assay buffer for all of the protein markers except 
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osteocalcin, which was diluted 1:20. Three separate assays were done, one using 3 antibody 
immobilized beads consisting of Il-6, OPG, and TNF-α, and two other assays were run on 
OCN and RANKL single immobilized beads. The plates were read using a Luminex Magpix 
platform (Luminex, Austin, TX) to identify the fluorescence of the secondary 
antibody/streptavidin reporter. Standard curves were generated using standards with known 
concentrations for all the analytes run. MFIs (median fluorescent intensity) were generated 
and used to determine the concentration of each analyte. Serum from LOXL1 -/-, LOX +/-, 
and wildtype non-diabetic, diabetic vehicle injected, and amisulpride injected mice was also 
analyzed for bone turnover markers procollagen type I N-terminal peptide (PINP) and cross-
linked C-telopeptide of type I collagen (CTX-1) using ELISA assays according to the 
manufacturer (MyBiosource, San Diego, CA, catalogue # MBS736256 and catalogue# 
MBS2014019 ). Serum from wildtype non-diabetic, wildtype diabetic vehicle injected, and 
wildtype diabetic amisulpride injected mice was also analyzed for dopamine (Mybiosource, 
San Diego, CA catalogue #MBS732020) and insulin (Thermofisher catalogue #EMINS).  
 
Isolation of RNA 
 
Total RNA was extracted from the tibiae of LOX +/- diabetic and non-diabetic mice, 
as well as amisulpride and vehicle injected diabetic and non-diabetic control mice. The tibia 
from each individual mouse was snap frozen in liquid nitrogen and ground to a fine powder 
using a mortar and pestle. The resulting powder was transferred to 1mL of Trizol extraction 
buffer and RNA extracted using 0.2 mL chloroform. Samples were centrifuged, the aqueous 
phase removed, and further extraction performed using 1:1 volume of isopropyl alcohol. 
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RNA was further purified using an RNeasy mini kit (Qiagen catalogue #74004). cDNA was 
synthesized from 1 µg total RNA using Taqman Reverse Transcription Reagents (Applied 
Biosystems catalogue #N8080234). cDNAs were then subjected to real time PCR analysis 
(Taqman gene expression) using Applied Biosystems 7300 Real-Time PCR systems to 
measure lysyl oxidase mRNA levels using Taqman probes from Applied Biosystems: mouse 
lysyl oxidase (Mm00495386_m1) and GAPDH internal control (Hs02786624_g1). Results 
were calculated using the 2-(ΔΔCT) relative quantification method. To convert to negative fold 
change the values that were less than 1, the negative reciprocal was taken of the value 
obtained after calculation of 2-(ΔΔCT). 
 
SIGNALING STUDIES 
 
Cell Culture and Analysis of LOX RNA and Protein Levels 
 
 For initial signaling studies to elucidate the GIP signaling pathway in osteoblasts, 
the calvarial pre-osteoblast cell line MC3T3-E1-E1 was used (ATCC CRL-2593). Cells 
were cultured in α-MEM medium supplemented with 10% FBS and 1% 
penicillin/streptomycin. Cells were replated in 6 well plates at a density of 1x106 cells per 
well. Cells were serum starved overnight and then treated with 0, 1, and 10 nM GIP (Tocris 
catalogue #2084) as well as 10 μM forskolin, an adenylyl cyclase agonist. Cells were also 
pretreated with 100 µM of the adenylyl cyclase inhibitor SQ22536 (Tocris catalogue 
#1435) and the myrisolated PKA inhibitor PKI-22 (Enzo Life Sciences BML-P210-0500) 
for 30 minutes before treatment with either GIP or forskolin. RNA was extracted using the 
RNeasy mini kit described previously and subjected to RT-qPCR using the same LOX gene 
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Taqman probe described previously. For absolute quantification, data were calculated 
based on a standard curve of known transcript copy numbers and normalized to the amount 
of cDNA added. Briefly, LOX cDNA was serially diluted to known concentrations and a 
standard curve was generated where concentration was plotted against Cq quantification 
cycle values. Cq values from unknown samples were obtained by qPCR and concentration 
was extrapolated from the standard curve and converted to copy number. Protein was 
extracted by lysing cells directly in protein sample buffer (0.5M Tris, 10% glycerol, 2.5% 
SDS) and lysates were subjected to western blotting to measure the levels of LOX protein. 
Medium was also taken from these same cells, and concentrated by centrifugation through 
an Amicon Ultra 10K filter (Amicon catalogue #UFC801096). For Western blotting, 
samples were separated on a 10% SDS-PAGE gel and transferred to a PVDF membrane 
overnight. Membranes were blocked for 2 hours in 5% non-fat dry milk in TBS-T and then 
incubated with the previously described LOX antibody at a dilution of 1:1000.  Membranes 
were then washed three times with TBS-T followed by 2 hours incubation with anti-rabbit 
horseradish peroxidase (HRP) coupled IgG at a 1:2000 dilution. Membranes were washed 
again and then sprayed in the dark with HyGlo Quick spray (Denville Scentific catalogue 
#E2400), with reacts with HRP to create a chemiluminescent reaction whose intensity can 
be captured and imaged using the SynGene GBox and Genesys software which keeps the 
exposures the same for all images. The membranes were then stripped using Restore 
Western Stripping Solution (Pierce) and re-probed with anti-β-actin antibody (Cell 
Signaling antibody #4967) as a loading control.  
  
  
37 
To study the effects of diabetes on osteoblasts, primary osteoblasts were isolated 
from the right and left tibiae of diabetic and non-diabetic control mice (Bakker and Klein-
Nulend 2012). The Boston University Institutional Animal Care and Use Committee 
(IACUC) approved all animal protocols. Mice were sacrificed by cervical dislocation. 
Then, the abdomen and extremities were rinsed in 70% ethanol. An incision around the 
perimeter of the hind limbs where they attach to the trunk was made and the skin was 
removed by pulling toward the foot, which is cut at the anklebone. This eliminates further 
contact of the hind limb with the animal's fur, which is a source of contaminating bacteria. 
The hind limbs were dissected from the trunk of the body by cutting along the spinal cord 
with care not to damage the femur. Each hind limb was bisected into the femur and tibiae 
by cutting through the knee joint. The muscle and connective tissue from both the tibiae 
was removed by scraping the diaphysis of the bone clean and then pulling the tissue toward 
the ends of the bone. The clean diaphysis were cut into little pieces of approximately 1-2 
mm2 using scissors and fragments were placed in a 5 mL culture flask. The bone pieces 
were then washed several times with PBS and incubated in 4 mL collagenase II solution (2 
mg collagenase II powder (Thermofisher Scientific catalogue #17101015) per mL DMEM, 
made fresh and filter sterilized) at 37oC on a shaking platform in order to remove all 
remaining soft tissue and adherent cells. After 2 hours, the bone pieces were rinsed three 
times with DMEM supplemented with 100 µg/mL ascorbate and 10% FBS that was made 
fresh before each medium change and filter sterilized. The bone pieces were then 
transferred to 25 cm2 flasks, containing 5 mL medium, at a density of about 20 fragments 
per flask. Adult mouse bone cells started to migrate from the bone chips after about 2 days. 
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At about 4 days, cells and medium were either harvested for protein and RNA isolation, or 
cells were re-plated at a density of 2.5-5 x 103 cells per cm2 for signaling experiments by 
incubation for 10 minutes in 0.25% trypsin. For signaling experiments cells were pooled 
as needed. For differentiation experiments, cells were grown to approximately 60-70% 
confluency and growth medium was replaced with osteogenic differentiation medium (α-
MEM containing freshly prepared ascorbic acid (50 μg/mL), β-glycerophosphate (10 mM), 
and dexamethasone (10 nM)). During the course of differentiation the media was refreshed 
every three days. Experiments with differentiated mouse primary osteoblasts were 
conducted on day 14 and day 21. Total RNA and protein was extracted by direct lysis of 
diabetic and non-diabetic primary cells described previously. RNA was also isolated from 
differentiated diabetic and non-diabetic primary cells and subjected to RT-qPCR. Taqman 
probes used are as follows: Osterix (SP7) (Mm04933803_m1), RUNX2 
(Mm00501584_m1), Osteocalcin (BGLAP)(Mm03413826_mH), BSP(IBSP) 
(Mm00492555_m1), and DMP-1(Mm01208363_m1). Non-diabetic primary cells were 
also re-plated in 6 well plates, treated with 0, 0.1, 1, and 10 nM concentrations of GIP for 
4 hours, and RNA was isolated and subjected to RT-qPCR analysis using Taqman probes 
for LOX (Mm00495386_m1), LOXL1 (Mm01145738_m1), LOXL2 (Mm00804740_m1 
), LOXL3 (Mm01184865_m1) and LOXL4 (Mm00446385_m1).  
 
cAMP assay 
 
MC3T3-E1-E1 osteoblasts were plated in 96 well plates, serum starved overnight, 
and treated with 0, 0.1, 1 and 10 nM GIP, as well as 10 µM forskolin, for 4 hours in the 
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presence of 10 μM IBMX, a phosphodiesterase inhibitor. Cells were also pretreated with 
100 μM of the adenylyl cyclase inhibitor SQ22536 for 30 minutes before treatment with 
either GIP or forskolin. Cells were lysed in 6N HCl and subjected to a radioimmunoassay 
for cAMP. Assays were performed by the cell signaling core at the Center for Skeletal 
Research at Massachusetts General Hospital (P30 AR066261). Conditions were run in 
triplicate and the assay was performed three times. 
 
Analysis of PKA Activity  
 
 MC3T3-E1 cells were plated in 6 well plates, serum starved overnight and treated 
with 0, 0.1, 1, 10, 100, 200 nM and 1 µM GIP, as well as forskolin for 1 hour, and also 
pretreated for 30 minutes with the myristolated PKA inhibitor PKI-22. Cells were lysed 
directly in protein sample buffer and lysates were subjected to western blotting (previously 
described) to measure the levels of phosphorylated CREB and total CREB. Blocked PVDF 
membranes were incubated with an antibody specific for phosphorylation site Ser133 on 
CREB (Cell Signaling rabbit mAb #9198) at a dilution of 1:000 and imaged using the 
SynGene GBox and Genesys software. The membranes were then stripped and reprobed 
with anti-total CREB antibody (Cell Signaling rabbit mAb #9197) to measure total 
endogenous levels of CREB to normalize phospho-CREB levels. Densitometry analysis 
was carried out using the gel analyzer feature of the Image J software according to the user 
manual (IJ version 1.46r, section 30.13). The phospho-CREB levels were reported as a 
ratio of phospho-CREB band to total CREB band intensity levels.  
 
LOX Promoter Studies 
  
  
40 
 
The 2.5 kbp mouse lysyl oxidase promoter DNA extending from −2,073 bp 
upstream from the translation start site to position +434 bp was re-cloned into the pGL4.10 
luciferase reporter construct (Promega cat# E6651). Site directed mutagenesis was 
performed using the QuickChange II XL Site-Direct Mutagenesis Kit (Genomics Agilent 
cat#200521) to mutate three TCF/LEF conserved consensus sequences (Table 1) within the 
lysyl oxidase promoter. TCF/LEF binding elements were selected based on in silico 
analyses of putative element locations and conservation between species using PROMO 
v.3 and TRANSFAC 7.0 software (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 and http://www.gene-
regulation.com/pub/databases.html#transfac), all as previously described (Khosravi, 
Sodek, Xu, et al. 2014). FuGene-6 reagent (Roche catalogue # 11914443001) was used to 
transiently transfect MC3T3-E1 cells with the wildtype non-mutated lysyl oxidase 
promoter firefly-luciferase construct and the TCF/LEF mutated lysyl oxidase promoter 
firefly-luciferase constructs. Cells were co-transfected with the renilla luciferase thymidine 
kinase luciferase reporter construct as control for positive transfection (pRL-TK, Promega 
catalogue #E2241). DNA:FuGene-6 ratio was 1∶3 (0.33 µg DNA/1 µl FuGene-6 per well 
of a 24-well plate to a final volume of 300 µl per well). Cells were incubated with the 
DNA:FuGene-6 mixture in serum-and antibiotic-free media for 6 hours. Cells were then 
fed with fresh medium, and after 24 hours medium was replaced with serum-free medium 
containing 0.1% BSA. Cells were then treated with 10 nM GIP (determined to be optimal) 
for 4 hours. Cells were lysed, and firefly and renilla luciferase activities were separately 
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measured using a Dual Luciferase Reporter Assay System (Promega catalogue #E1910). 
The data were first normalized by calculating the ratio of firefly to renilla luciferase activity 
then presented as a fold change between GIP treated and control cells.  
To confirm TCF/LEF involvement in the GIP/LOX signaling pathway, a 
TOP/FLASH assay was performed (Qiagen Cignal Reporter Assay Kit, TCF/LEF, 
catalogue #CCS-018L). MC3T3-E1 cells were transfected with either a positive control, 
which is a constitutively active TCF/LEF luciferase reporter construct, a negative control, 
which is a mutated TCF/LEF luciferase reporter construct, or an inducible TCF/LEF 
luciferase reporter construct. Cells were also co-transfected with the same previously 
described renilla luciferase reporter construct. Cells were then treated with GIP for 4 hours 
and luciferase activity measured and reported as a ratio of firefly to renilla luciferase 
activity.  
To investigate β-catenin involvement in the GIP/LOX pathway, β-catenin 
expression was knocked down in MC3T3-E1 cells using a β-catenin shRNA construct 
(custom synthesized by Sigma Aldrich). Cells were transiently transfected with the shRNA 
construct plasmid using FuGene6 as previously described. Cells were also transfected with 
an empty plasmid as well as a non-target shRNA construct against GFP as controls. Cells 
were grown to confluence for 24 hours and then changed to medium containing 4 µg/mL 
puromycin to select for transduced cells. After two days, cells were transfected with the 
previously described wild-type LOX promoter luciferase reporter construct, as well as the 
renilla luciferase reporter construct. Cells were then serum starved overnight and treated 
with GIP for 4 hours. The data were first normalized by calculating the ratio of firefly to 
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renilla luciferase activity then presented as a fold change between GIP treated and control 
cells. Protein was also isolated by direct lysis of cells in protein sample buffer and analyzed 
by Western blot with a β-catenin (Santa Cruz catalogue #7963) and LOX antibody to 
examine their respective protein levels as previously described.  
 
Dopamine Inhibition Studies 
 
 Primary bone cells were isolated from non-diabetic control mice as described above 
and cells were plated in 96 and 6-well plates. Cells were pre-treated with dopamine 
hydrochloride (sigma Aldrich catalogue #H8502) at concentrations of 0, 10, and 100 nM 
and 1, 10, and 100 µM for 30 minutes before treatment with 10 nM GIP for 4 hours. cAMP 
assays and western blotting for LOX protein levels were then performed as previously 
described. Primary bone cells isolated from non-diabetic and diabetic mice were also plated 
in 96 and 6-well plates. Cells were pretreated with the dopamine receptor inhibitor 
amisulpride (previously described) at a concentration of 20 μM for 30 minutes before 
treatment with GIP for 4 hours. cAMP assays and qRT-PCR for LOX mRNA levels were 
performed as previously described.  
 
Statistical Analysis 
 
All signaling experiments were run in triplicate and performed three times. For all 
µCT, histology, and serum ELISA experiments involving our mouse models, there was an 
n of 8 per group for LOXL1 -/-, an n of 6 per group for LOX +/- experiments, and an n of 
10 for all other experiments. One way ANOVA with Tukey’s post-hoc test for specific 
differences in between groups was employed for all analyses involving multiple groups, 
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and student’s T-test employed for all other analyses. Significance was declared as p<0.05. 
Data are presented as means +/- standard deviation.  
 
RESULTS 
 
Part I: Sex-linked Skeletal Phenotype of Lysyl Oxidase Like-1 Mutant Mice 
 
Sex-Specific Effects of LOXL1-/- on Trabecular Bone Parameters 
LOXL1 was ablated from the mice homozygous for the mutated allele at the DNA 
(Figure 1) and LOXL1 protein expression was assessed by immunohistochemistry with an 
antibody specific for the unique N-terminus of LOXL1 (Figure 2). This was indicated by 
the presence of chondrocyte and extracellular matrix-associated LOXL1 staining in the 
growth plates of sections made from wild type mice, and the absence of staining in the 
LOXL1-/- male and female femur sections, and all IgG isotype control stained serial 
sections (Figure 2). No staining was observed in osteoblasts or in cortical bone in any 
samples suggesting that LOXL1 long bone expression occurs primarily in chondrocytes in 
13 week old mice. Knockout mice were viable and grossly normal. Comparisons of weight 
and femur length indicate that mutant and wild-type controls were similar in size (Table 
1). Three dimensional reconstructions of the μCT scans of the distal metaphysis of the 
femur and the L5 vertebrae show clear abnormalities in trabecular architecture in LOXL1-
/- female mice relative to wild-type littermates, (Figure 3 A-H). Full-length bone scans of 
the femur corroborate these results and further indicate that femur length is unaltered in 
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spite of trabecular abnormalities (Figure 3I-L). These images show that these abnormalities 
are primarily seen in LOXL1-/- females, while the LOXL1-/- males more closely resemble 
their wild-type counterparts. This is supported by quantitative analyses computed from the 
μCT scans (Figure 4 and Figure 5).  
Bone volume (BV) was significantly lower in the female, but not in the male, 
LOXL1-/- mice as compared to their wild-type counterparts, whereas total volume was 
similar for both female and male mutant phenotypes compared to wild-type (Figure 4 A 
and B). This is reflected in significant decreases in BV/TV ratios in LOXL1-/- females 
compared to WT females (p-value < 0.001) (Figure 4 C). In the trabeculae, connective 
density (Conn.D, Figure 4 D), trabecular number (Tb.N, Figure 4E) were decreased, 
trabecular spacing was increased (Tb.Sp, Figure 4F), and trabecular thickness (Tb.Th, 
Figure 4G) was decreased significantly in LOXL1-/- females (p-value <0.01). 
Interestingly, these changes in trabeculae were not observed in LOXL1-/- males. Hence, 
all μCT trabecular parameters tested were significantly affected in female, but not male, 
LOXL1-/- mice. In contrast, cortical bone parameters were not significantly altered in 
either female or male LOXL1-/- femurs relative to respective wild-type controls (Table 2).  
To corroborate results observed in the distal metaphysis of the femur, trabeculae of 
the L5 vertebrae were analyzed using the same parameters employed for the femurs. The 
L5 vertebrae also showed significantly low trabecular bone parameters that were sex-
specific, compared to their wild-type controls. Specifically, bone volume was significantly 
low in LOXL1-/- females while total volume remained the same across all four genotypes 
(BV, Figure 5A and B). The results, therefore, reflect significant decreases in the BV/TV 
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ratios in trabeculae of LOXL1-/- females compared with wild-type (p-value <0.001) 
(Figure 5 C). There were no such effects observed in LOXL1-/- males. Furthermore, 
connective density (Conn.D, Figure 5D), trabecular number (Tb.N, Figure 5E), and 
trabecular thickness (Tb.Th, Figure 5G) were decreased in LOXL1-/- females, but not 
LOXL1-/- males (p < 0.01). There were no significant differences in trabecular spacing nor 
in the cortical parameters of the cortical shell of the L5 vertebrae in any of the mice (Table 
2). Together, these results indicate a defect in the trabecular bone architecture of female 
LOXL1-/- mice, which was not observed in cortical bone.  
Histological Analysis of Bone Resorption and Formation 
To determine if increased bone resorption contributed to defective trabecular 
patterns in LOXL1-/- mice, bones were stained for TRAP activity.  Representative images 
clearly show a high concentration of TRAP stain and TRAP positive osteoclasts (Figure 6 
C-E) in the LOXL1-/- females. The number of osteoclasts was next quantified by counting 
TRAP positive, multinucleated cells.  The number of osteoclasts per millimeter of bone 
area was increased dramatically in LOXL1-/- females compared to their wild-type 
counterparts (p< 0.0001, Figure 7A). These results indicate increased resorptive activity in 
LOXL1-/- female mice. There was no statistically significant increase in TRAP positive 
cells seen in LOXL1-/- males (Figure 7A).  
The number osteoblasts per millimeter of bone surface was quantified by counting 
cuboidal, light purple, clustered cells with an asymmetric nucleus associated with the bone 
surface in hematoxylin and eosin stained central sections. There were no significant 
differences between any of the genotypes (Figure 7B). Therefore the increase in bone 
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resorption as indicated by increased osteoclast number is not accompanied by an increase 
in bone formation as quantified by osteoblast number. If bone formation were to increase 
with bone resorption, total bone turnover would remain the same. Instead this cytometric 
analysis points to a cellular uncoupling of bone turnover processes favoring increased 
resorption as measured by the ratio of osteoclasts to bone-generating osteoblasts (Figure 
7C), consistent with the bone deficits evaluated by micro-CT.  
Histological Analysis of Cartilage Growth Plates  
 Representative images of growth plates shown in Figure 8 indicate that columns 
lack a normal organization in all knockout mice, although the effects were more 
pronounced in the knockout female mice (Figure 8). Quantitative analyses of the growth 
plates revealed significantly lower numbers of chondrocytes per column in both LOXL1-
/- females and males in comparison to their wild-type counterparts (p< 0.0001) (Figure 
8E). The average growth plate height and chondrocyte density were not significantly 
affected in mutant mice however (data not shown), consistent with very similar femur 
lengths in mutant mice compared to wild-type mice (Table 1).  
Analysis of Bone Biomarkers in Serum 
Serum was isolated from all mice at 13 weeks of age and analyzed for selected 
metabolic bone markers using the Milliplex immunoassay system. Two biomarkers 
showed significant differences in LOXL1-/- females only. There was a significant increase 
in receptor activator of nuclear factor kappa-B ligand (RANKL), a ligand that binds to its 
corresponding receptor RANK on osteoclast progenitor cells and induces osteoclast 
differentiation (Figure 9A) (p-value < 0.01). To exacerbate this effect, there was also a 
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significant decrease in osteoprotegerin (OPG), the soluble decoy receptor for RANKL 
(Figure 9B) (p<0.01) resulting in an increase in the RANKL/OPG ratio (Figure 9C). 
Interestingly, there were no significant differences seen in the RANKL/OPG ratio in 
LOXL1-/- males compared to their wild-type counterparts. There were no significant 
differences in interleukin-6, TNF-α, or osteocalcin concentration between the groups 
(Figure 9 D-F). These results are generally consistent with the μCT and histological 
characterizations summarized above and indicate that there is sex-specific dysregulation 
occurring that drives the observed phenotype, though the lack of significant change in IL-
6 and TNF-α was not expected.  
To further extend the histomorphometric data showing evidence for increased bone 
resorption, serum was analyzed for bone turnover markers procollagen type I N-terminal 
propeptide (PINP) which is a sensitive marker for bone formation, and C-terminal 
telopeptide (CTX-1) which is a cross-linked peptide of type I collagen and the most specific 
marker for bone resorption (Vasikaran et al. 2011). Results indicate not only a significant 
increase in CTX-1 in female LOXL1-/- mice compared to their wild-type counterparts 
(Figure 10A, p < 0.05), which validates the increased number of osteoclasts seen in these 
mice, but also a significant decrease in PINP (Figure 10B, p < 0.01), indicating an actual 
decrease in bone formation in female LOXL1-/- mice compared to their wild-type 
counterparts. No such difference was observed in male LOXL1-/- mice. 
 
Part II: Incretin Dysregulation of Lysyl Oxidase: A Novel Mechanism for Diabetic 
Osteopenia 
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GIP upregulates LOX by an adenylyl cyclase/cAMP/PKA dependent pathway in 
osteoblasts 
 
While previous studies have shown that GIP causes an increase in bone formation 
and lysyl oxidase collagen cross-linking activity in osteoblasts (Mieczkowska et al. 2015; 
Xie et al. 2007), the specific mechanisms by which GIP upregulates lysyl oxidase have not 
been investigated. We therefore sought to determine the downstream effectors in this 
pathway under normal conditions to better understand what is being affected in diabetic 
conditions.  
To first provide direct evidence that GIP upregulates lysyl oxidase mRNA and to 
determine which isoform is predominantly affected, primary osteoblasts isolated from 
wildtype C57BL/6 male and female mice and the calvarial osteoblast line MC3T3-E1-E1 
cells were treated with a time course of GIP at concentrations ranging from 0.02 nM to 1 
nM. Relative RNA expression of the lysyl oxidase isoforms normalized to a GAPDH 
internal control was determined by qRT-PCR for all five paralogues of LOX. This was 
important to determine because each paralogue is regulated independently and involved in 
different signaling pathways (Csiszar 2001; Pischon et al. 2009). Data show that LOX is 
upregulated more than 8-fold at 1 nM GIP in MC3T3-E1 osteoblasts (Figure 11A) and 
more than 10-fold at 1 nM GIP in primary osteoblasts (Figure 11B) after 24 hours, while 
the other LOX isoforms exhibit only modest up-regulation. Thus, the predominant isoform 
targeted by GIP in osteoblasts is LOX. This finding provides the first direct evidence that 
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GIP strongly increases LOX expression, and supports the hypothesis that loss of GIP 
regulation of LOX in diabetes is largely responsible for decreased collagen cross-linking 
and osteopenia observed in diabetes. 
The receptor for GIP (GIPR) is a class II G-protein coupled receptor (GPCR) whose 
activity is mediated mainly through the Gsα protein subunit (Trzaskowski et al. 2012). 
Based on previous research on other osteoblast expressed GPCRs (Silva and Bilezikian 
2015), the most likely pathway activated by these types of receptors is the adenylyl cylase/ 
cAMP/PKA pathway. cAMP acts mainly through protein kinase A (PKA) by binding to its 
regulatory subunit, resulting in PKA activation (Glass et al. 1989). Previous studies have 
shown that GIP signaling is dependent on the production of cAMP by adenylyl cyclase in 
pancreatic β-cells (Drucker 2006). However, inhibitors of PKA do not completely abrogate 
the effects of GIP on insulin secretion in β-cells (Lynn et al. 2003), suggesting the potential 
involvement of additional non-canonical pathways activated by the GIP receptor. To 
evaluate the extent to which cAMP signaling mediates GIP regulation of LOX, the calvarial 
osteoblast cell line MC3T3-E1-E1 was treated with GIP at concentrations ranging from 0.1 
nM to 1 µM for 4 hours. These cells were then assessed for increases in cAMP production 
using RIA analysis. This experiment was also performed in the presence of the adenylyl 
cyclase agonist forskolin and the adenylyl cyclase inhibitor SQ2256 to confirm the 
contribution of this enzyme to changes in cAMP levels. Data show that treatment of 
MC3T3-E1 cells with GIP results in an increase in cAMP levels starting at concentrations 
of 0.1 nM, with optimal production of more than 20 fmol/µL cell lysate occurring at 
concentrations of 10 nM GIP after 4 hours (Figure 12). These levels were similar to that of 
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forskolin at 10 nM GIP, and increases in cAMP are reversed back to baseline if cells are 
pretreated with an adenylyl cyclase inhibitor, confirming the specificity of GIPR signaling 
through adenylyl cyclase.  
To determine if GIP causes an increase in PKA activity, the phosphorylation of the 
downstream targets of PKA were determined by Western blot as a measure of kinase 
activity. PKA activating phosphorylations of its major substrate CREB were determined 
using phospho-CREB antibodies normalized to total endogenous CREB. The contribution 
of PKA to LOX regulation was also assessed by treating MC3T3-E1 cells with the selective 
myristoylated PKI 14-22 amide peptide PKA inhibitor in response to GIP treatments 
(Khosravi, Sodek, Xu, et al. 2014). GIP causes an increase in CREB phosphorylation in 
MC3T3-E1 osteoblasts, which seems to be optimal at lower concentrations with 
concentrations of about 1 nM having similar band intensities to forskolin treatment (Figure 
13). Pre-treatment with the PKA inhibitor PKI 14-22 reverses this increase back to baseline 
levels. This confirms PKA enzymatic activity is increased in response to GIP, however 
there may be desensitization occurring at higher concentrations of GIP. 
To show the direct involvement of both cAMP and PKA in LOX regulation, 
differences in levels of LOX were also examined at the RNA and protein level by 
pretreatment of MC3T3-E1 cells with forskolin, SQ2256, and the myristoylated PKA 
inhibitor PKI-22 before treatment with 10 nM GIP, which we have determined to be the 
optimal dosage. Results from qRT-PCR and Western blotting analysis of cell extracts show 
the increase seen in cAMP and PKA enzymatic activity in response to GIP was 
accompanied by an increase in LOX transcript (more than 10-fold, Figure 14) and 
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intracellular protein levels (Figure 15), with the two bands on the western blot for LOX 
corresponding to different glycosylated forms of LOX during its ER processing. 
Pretreatment with both the adenylyl cyclase and PKA inhibitor dramatically reverses this 
effect at both the RNA and protein level (Figures 14 and 15), suggesting that GIP 
stimulated increases in LOX expression in osteoblasts is dependent on both cAMP 
production by adenylyl cyclase and PKA enzymatic activity. 
 
GIP-stimulated increases in LOX transcriptional activity in osteoblasts is dependent on 
β-Catenin mediated promoter activation 
β- Catenin signaling is involved in the development of diabetes and is also 
important in directing osteogenic differentiation in mesenchymal stem cells (Liu and 
Habener 2010; Khosravi, Sodek, Xu, et al. 2014). β-Catenin exerts its effects mainly by 
complexing with and activating transcription factors of the TCF/LEF family, leading to the 
transcription of target genes (Liu and Habener 2008). Our laboratory has previously 
reported that there are functional TCF/LEF cis-elements in the lysyl oxidase promoter and 
has created and implemented TCF/LEF cis-element mutant LOX promoter luciferase 
reporter constructs to study LOX promoter modulation (Table 3) (Khosravi, Sodek, Xu, et 
al. 2014). These constructs or wild type control constructs were transfected into MC3T3-
E1 cells and LOX promoter activity was measured in response to GIP treatment. 
Transcriptional activity from the LOX promoter was increased in response to 10 nM GIP 
treatment (Figure 16). This induction was not seen in cells that were transfected with a 
construct with a mutation in a TCF/LEF conserved consensus sequence located -913 bp 
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upstream of the transcriptional start site (site 1 TCF mutant), or in any co-transfection of 
this construct with other mutated constructs that did not affect promoter activity (Figure 
16). This suggests the presence of a TCF/LEF inducible element in the LOX promoter that 
is essential for GIP stimulated LOX transcription.  
The ability of GIP to specifically activate a TCF/LEF mediated response was 
confirmed using a TOP-FLASH assay (Ahrens, Romereim, and Dudley 2011). MC3T3-E1 
cells were transfected with either an inducible TCF/LEF responsive luciferase reporter 
construct, or a constitutively active or mutated positive and negative control, respectfully. 
TCF/LEF promoter elements show a significant increase (p<0.001) in transcriptional 
activity in response to GIP treatment compared to untreated controls, confirming TCF/LEF 
transcription factor involvement in GIP mediated signaling. This effect was not seen in the 
negative control (Figure 17). 
The contribution of β-catenin to the activation of the LOX promoter by GIP was 
also evaluated by co-transfecting MC3T3-E1 cells with the wild type LOX promoter 
reporter construct and a shRNA β-catenin knockdown plasmid. Results show that cells with 
significantly reduced β-catenin protein levels (Figure 18B) were unable to induce a 
response from the LOX promoter in response to GIP (Figure 18A, p<.01). Furthermore, in 
β-catenin knockdown cells there was very little LOX protein present in cell lysates 
evaluated by western blotting (Figure 19), further confirming the involvement of β-catenin 
in LOX regulation in osteoblasts. Taken together, these promoter studies point to a β-
catenin dependent mechanism for GIP mediated increases in LOX expression in osteoblasts 
in which β-catenin/TCF/LEF transcription factor complexes activate TCF/LEF inducible 
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cis-elements in the LOX promoter, resulting in increased transcription from the LOX 
promoter. 
Diabetic and LOX +/- mice have a decrease in bone quality 
Eight week old male and female wild type and LOX +/- littermate mice were 
developed according to previous studies (Hornstra et al. 2003; Alsofi et al. 2015). To study 
how LOX mediates diabetic osteopenia, a subset of each of these mice was made diabetic 
by low dose streptozotocin-induction, and became diabetic by 12 days (>250 mg/dl serum 
glucose) (n=8) and mice remained diabetic for an additional 8 weeks. Steptozotocin is toxic 
to pancreatic β-cells and is therefore a model for type I diabetes. We first examined if LOX 
+/- mice, who are osteopenic, could recapitulate the specific bone phenotype seen and 
documented in diabetic mice, i.e. bone abnormalities that are more severe in the 
metabolically active trabecular bone and in the axial as opposed to the appendicular 
skeleton (Botolin and McCabe 2007; Kemink et al. 2000; Vestergaard 2007). Mice were 
sacrificed 8 weeks after diabetes induction, bones dissected, and scanned using a Scanco 
Medical µCT40 Scanning instrument. LOX +/- mice showed a similar defect in trabecular 
structure in the femur as that of diabetic mice (Figure 20A). Quantitation of data according 
to established parameters (Bouxsein et al. 2010) shows the bone volume/total volume 
(BV/TV), connectivity density (Conn.D), and trabecular spacing (Tb.Sp) are all affected 
similarly in LOX +/- and diabetic mice (Figure 20 B). Interestingly, diabetic mice haploid 
for LOX exhibited a profound exacerbation of this effect as seen in the 3-D tomogram 
(Figure 20 A) and confirmed in BV/TV, connectivity density, and trabecular spacing 
(Figure 20 B). This suggests that LOX is either directly or indirectly mediating the 
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osteopenia seen in the diabetic mice. There were no significant differences in BV/TV in 
the cortical bone in any group, reminiscent of what occurs in diabetes (Figure 21). 
Examination of the L5 vertebrae also shows that diabetic and LOX +/- mice have a similar 
trabecular defect (Figure 22). However, this defect is not as severe as that seen in the femur, 
with significant differences only seen in the BV/TV and trabecular spacing (Figure 22), 
consistent with results seen in diabetic mice and patients (Kemink et al. 2000). The pattern 
of increased severity in LOX +/-, diabetic mice is also maintained in the vertebrae.  
Diabetic Mice have reduced osteoblast numbers and activity 
Since diabetes is a low bone formation disease (Kalaitzoglou et al. 2016), we next 
examined osteoblasts, the bone forming cells, to see if there was a reduction in either 
number or activity in diabetic and LOX +/- mice. Immunohistochemistry was performed 
using an anti-osteocalcin antibody to positively identify osteoblasts and the number of 
osteoblasts per mm bone surface in the region directly below the growth plate in the 
trabecular bone was quantified. Diabetic mice had significantly fewer osteoblasts in the 
trabecula compared to wildtype non-diabetic mice (Figure 24A, p<0.001), and very little 
positive immunostaining was seen (Figure 23). LOX +/- mice however did not differ 
significantly from the wildtype mice in osteoblast number, indicating that osteoblast 
number is independent of LOX haploinsufficiency (Figure 24A). However, when we 
examined PINP levels as a serum readout for bone formation, LOX +/- mice did have lower 
levels compared to wild type mice (p<0.01) and similarly low PINP levels to those of 
diabetic mice (Figure 24C). The defect in anabolic activity was exacerbated when diabetic 
mice were also LOX +/- (Figure 24C), indicating that decreased osteoblast activity in 
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diabetic osteopenia may be affected by decreased LOX levels. There was no difference in 
osteoclast activity between any of the groups (Figure 24B), which is typical of diabetic 
osteopenia.  
Diabetic and LOX +/- mice display changes in collagen structure 
Changes in BMD in diabetic osteopenia are not large enough to explain the increase 
in fracture risk in these patients (Vestergaard 2007). Therefore it is likely that changes in 
the amount of collagen or the collagen microstructure in diabetic bone is altered in diabetic 
osteopenia. Since LOX activity is required for collagen cross-linking, and the bone 
phenotype seen by micro-CT revealed LOX +/- bones display a similar osteopenia to that 
of diabetic mice, we also wanted to assess for defects in collagen organization in diabetic 
and LOX haploid mice. To examine this, picrosirius red histology was performed on central 
sections in all four groups. As can be seen in the non-polarized light panel, the amount of 
collagen is similar between all four groups (Figure 25, left panel). However, under 
polarized light the diabetic and LOX +/- mice have a very different birefringence profile 
than that of wild-type mice (Figure 25, right panel). In picrosirius red histology, the picric 
acid can dissolve collagen fibers that are loosely packed. When picric acid is able to 
penetrate the collagen, the sirius red dye can stain the collagen more effectively, resulting 
in a dark red stain under non-polarized light and bright yellow birefringence under 
polarized light. When the stain is unable to penetrate the collagen due to tight fibril packing, 
the collagen profile looks like it does in the wild-type mice (Figure 25); the staining is dull 
and the birefringence is mixed with evidence of green, yellow, blue, and some orange red 
and yellow. The osteocytes and lacunae can also be seen even under polarized light, 
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indicating the bone is in an organized formation and higher order structure. However in the 
diabetic and LOX +/- mice and especially in the diabetic, LOX +/- mice there is a lot of 
bright yellow collagen fibers that are striated in appearance, indicating that the collagen is 
in loosely packed bundles that are poorly organized (Figure 25). This indicates that diabetic 
mice have defective collagen structure, and this is exacerbated when LOX levels are also 
decreased in these diabetic mice. Since LOX is responsible for maintaining collagen 
integrity, the exacerbation of the defect in collagen structure upon LOX haploinsufficiency 
in diabetes indicates that LOX could be a major player in the pathology of diabetic 
osteopenia, mediated by its collagen cross-linking activity.  
 
Diabetic mice have decreased LOX expression 
To confirm our hypothesis that LOX is involved in the phenotypic variation we 
observed in our non-diabetic and diabetic wild type and LOX +/- mice, levels of LOX were 
examined in all four groups. To this end, we isolated RNA directly from the tibiae of the 
diabetic and LOX +/- mice and performed qRT-PCR using a probe for LOX. Results show 
a more than 20 fold decrease in LOX mRNA levels in diabetic bone, beyond that seen in 
our LOX haploinsufficient mice (Figure 26). LOX mRNA levels are further decreased to 
more than 30 fold in the LOX +/- diabetic mice (Figure 26). We suspect that exacerbated 
bone loss in haplosufficient diabetic mice observed in Figures  21 – 25 may be partially 
due to lower levels of LOX expression identified in Figure 26, suggesting that LOX 
regulation could be a critical factor in diabetic osteopenia in vivo. 
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Diabetic primary bone cells are producing lower amounts of LOX mRNA and protein 
Primary bone cells were isolated from the tibiae of diabetic and non-diabetic mice 
to examine their characteristics. First, primary bone cells from both mice were 
differentiated using osteogenic differentiation medium to confirm that bone cells were able 
to differentiate into mature osteoblasts. This was done to confirm the primary bone cell 
isolation was successful and that primary osteoblasts were not contaminated by 
hematopoietic cells or fibroblasts. RNA was isolated from diabetic and non-diabetic 
primary bone cells after three weeks in differentiation medium and subjected to qRT-PCR 
analysis for pre-osteoblast markers osterix and RUNX2, mature osteoblast markers 
osteocalcin and BSP, and late stage osteoblast differentiation marker DMP-1. Both non-
diabetic and diabetic bone cells were able to differentiate into osteoblasts that express high 
levels of osteocalcin, BSP, and DMP-1 (Figure 27), indicating that the cells isolated were 
in fact mainly osteoblasts. We also confirmed that these osteoblasts express mRNA 
transcripts for LOX and the LOX isoforms LOXL1-4 using absolute quantification qRT-
PCR on RNA isolated from primary bone cells after 4 days after culture, with the idea that 
they would still maintain their diabetic profile with a shorter culture time. LOX is the 
predominant isoform expressed in the primary osteoblasts, followed by LOXL1 (Figure 
28A). We then performed relative quantification on the qRT-PCR data using a GAPDH 
internal control. The amount of LOX and LOXL1-4 mRNA in diabetic primary osteoblasts 
was expressed as the percentage of the normal expression levels in wildtype non-diabetic 
primary osteoblasts. Results show that diabetic primary bone cells are only producing 
around 10% of the LOX produced by non-diabetic osteoblasts (Figure 28B). We also 
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isolated protein from non-diabetic and diabetic primary bone cells after 4 days in culture 
and examined LOX protein levels by western blot in both the cell lysate as a measure of 
intracellular LOX and in the concentrated medium as a measure of secreted LOX, which 
is important since LOX is active extracellularly. Data show that primary bone cells are not 
producing the same amount of intracellular LOX protein as non-diabetic primary bone cells 
(Figure 29 top panel), corroborating the qRT-PCR results and showing both transcriptional 
and translational defects in LOX production. Diabetic primary bone cells are also not 
secreting any detectable LOX in to the medium compared to the non-diabetic primary bone 
cells (Figure 29 bottom panel). These defects in LOX production and secretion by primary 
bone cells isolated from diabetic mice could explain the defects in collagen structure and 
trabecular abnormalities seen in these mice. 
 
Diabetic mice have increased serum dopamine levels 
After we had established that diabetic mice have decreased LOX levels, aberrant 
collagen structure, and decreased trabecular bone volume and defective trabecular 
structure, we next sought to identify the specific molecular mechanisms occurring in 
diabetes that are causing the decreased LOX levels and abnormalities in bone structure. In 
our signaling studies it was shown that the incretin GIP upregulates LOX via a cAMP 
dependent pathway, similar to that seen in the pancreas. Recent literature has identified 
gut-derived dopamine as an “anti-incretin” that can antagonize GIP signaling in the 
pancreas upon nutrient consumption, resulting in homeostatic glucose control in healthy 
individuals (Maffei et al. 2015). In diabetes, the pancreas no longer produces sufficient 
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insulin in response to GIP (Holst et al. 2011; Nauck et al. 1993). It is also known that 
diabetic patients that undergo bariatric surgery, which decreases peripheral dopamine 
levels, show an increase in glucose dependent insulin secretion and partial rescue of 
hyperglycemia (Chaudhry et al. 2016). All five receptors for dopamine are expressed on 
osteoblasts (Lee et al. 2015). We therefore hypothesized that increased gut-derived 
dopamine in diabetes could cause diabetic osteopenia by antagonizing the GIP signaling 
pathway in osteoblasts. To justify looking at dopamine as a potential culprit for diabetic 
osteopenia, we first performed an ELISA for dopamine on serum isolated from our diabetic 
and non-diabetic control animals after they had been diabetic for 8 weeks. Results show 
that serum dopamine is increased significantly in our diabetic mice (Figure 30, p=.0137, 
n=10) compared to the non-diabetic controls, suggesting that increased peripheral 
dopamine could be responsible for the diabetic bone phenotype seen in our mice. 
 
Dopamine inhibits GIP stimulated increases in cAMP production in osteoblasts 
In pancreatic β-cells, the dopamine receptor 2 (D2R) is the predominant receptor 
expressed and couples to G-protein complexes containing Gαi/o proteins that inhibit 
adenylyl cyclase from making cAMP, which antagonizes GIP stimulated increase in cAMP 
(Maffei et al. 2015). We next wanted to see if a similar mechanism was occurring in 
osteoblasts, since we had already shown that GIP causes an increase in cAMP in 
osteoblasts. We therefore performed RIA cAMP assays in MC3T3-E1 osteoblasts and this 
time pretreated for 30 minutes with concentrations of dopamine used in a previously 
published paper that had performed the same experiment in pancreatic β cells (Maffei et 
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al. 2015). Results show that with as little as 10 nM dopamine and optimal at 100 nM 
dopamine, pretreatment with dopamine before treatment with 10 nM GIP resulted in a 
significant inhibition of GIP stimulated increases in cAMP in MC3T3-E1 osteoblasts 
(Figure 31, p<.001), with cAMP levels resembling that of or below baseline levels in 
untreated osteoblasts. These results indicate that dopamine is able to inhibit GIP signaling 
in osteoblasts. 
Dopamine inhibits GIP stimulated increases in LOX production in osteoblasts  
To confirm our hypothesis that dopamine causes diabetic osteopenia by inhibiting 
LOX in osteoblasts, we also examined the ability of dopamine to inhibit the GIP stimulated 
increases in LOX protein production that we showed previously.  We therefore pretreated 
MC3T3-E1 and primary osteoblasts with the same concentrations of dopamine for 30 
minutes before treating cells with 10 nM GIP. We then isolated protein from cell lysates 
and subjected them to Western blotting for LOX protein. Results show that pretreatment 
with 10 nM dopamine can inhibit GIP stimulated increases in osteoblast LOX protein 
production, with complete inhibition of LOX protein below baseline untreated levels 
occurring at 1 µM in both cells lines (Figure 32). These results show for the first time that 
dopamine is able to inhibit LOX production in osteoblasts, which is an essential component 
of proper bone formation. These results combined with our results showing that there is 
increased gut-derived dopamine in diabetes offers a new mechanism for diabetic 
osteopenia that could have important implications for therapeutic development.  
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Inhibiting D2R signaling restores GIP stimulated cAMP production and LOX expression 
in diabetic primary bone cells 
We next wanted to examine if we could rescue GIP signaling and LOX production 
in osteoblasts using amisulpride, which is an inhibitor for the dopamine receptor D2R. 
Amisulpride has also been shown to restore insulin secretion in the pancreas, resulting in 
reduction in blood glucose readings in diabetic mice (Roix et al. 2012). We therefore took 
cultured primary cells isolated from diabetic and non-diabetic control mice and pretreated 
them for 30 minutes with 20 µM of amisulpride before treating them with 10 nM GIP. We 
wanted to determine 1) if primary bone cells isolated from diabetic mice were able to 
respond to GIP the same as the non-diabetic primary bone cells and 2) if they were unable 
to respond, if we could restore the GIP response by inhibiting signaling through the D2R. 
We therefore performed an RIA cAMP analysis as a readout for GIP receptor signaling 
and also examined LOX mRNA levels by qRT-PCR analysis of cell lysates in the presence 
and absence of amisulpride. Results show that GIP is able to stimulate an increase in cAMP 
in the primary bone cells isolated from non-diabetic mice, as shown previously, but failed 
to do so in primary bone cells isolated from diabetic mice (Figure 33A, p<0.05). This result 
holds true as well for LOX mRNA increases, where GIP treatment of primary bone cells 
isolated from diabetic mice fail to respond to GIP with an increase in LOX mRNA (Figure 
33B, p<0.01). This result supports our hypothesis that insensitivity to GIP signaling occurs 
in diabetes in osteoblasts, similar to what is occurring in the pancreas. Interestingly, when 
primary bone cells from diabetic mice were pretreated with the dopamine receptor 2 
inhibitor amisulpride, there was a restoration of cAMP signaling (Figure 33A, p<0.01), 
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indicating that the receptor can now stimulate adenylyl cyclase production of cAMP, and 
a restoration of LOX mRNA levels (Figure 33B p<0.01). These results therefore indicate 
that inhibition of D2R signaling can restore normal GIP signaling in osteoblasts, confirming 
that D2Rs are antagonistic against GIP receptors.  
 
In vivo administration of amisulpride restores normal trabecular bone volume and 
structure  
Amisulpride is already approved as a treatment for schizophrenia due to its ability 
to potently and specifically inhibit D2R signaling, resulting in a decrease in dopamine 
signaling, and its effects have been well studied in humans and mice (Roix et al. 2012). 
Based on our in vitro studies we hypothesized that in vivo administration of amisulpride at 
the therapeutic dosage of 10 mg/kg could potentially reverse the diabetic bone phenotype 
seen in our mouse model. We therefore intraperitoneally injected diabetic mice with either 
vehicle or amisulpride for 4 weeks after the 8 week mark of STZ-induced diabetes and 
compared the bone phenotype to that of non-diabetic control mice and diabetic mice 
injected with vehicle using micro-CT analysis. Results show that diabetic mice treated with 
amisulpride partially recover a normal trabecular bone phenotype, with the 3-D tomogram 
of trabecular bone resembling that of the non-diabetic control mice, and restoration to non-
diabetic control levels of the parameters BV/TV and trabecular spacing (Figure 34, n=10, 
difference from diabetic p-value <0.05). These results show for the first time that 
interference with dopamine signaling in diabetes restores normal bone health, making 
amisulpride a potential therapeutic for diabetic bone disease.  
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In vivo administration of amisulpride restores normal collagen organization and LOX 
mRNA levels 
To examine if this restoration in the bone phenotype is accompanied by a rescue of 
the aberrant collagen structure in diabetic bone, picrosirius red staining was performed on 
central sections from vehicle and amisulpride injected diabetic mice and compared to wild-
type control mice. Results show that amisulpride treated diabetic mice femur sections more 
resemble that of the wild-type, with less bright yellow than the diabetic mice and a more 
mixed birefringence profile indicative of an organized collagen structure and tightly packed 
collagen bundles, while vehicle injected diabetic mice maintain their less organized 
collagen structure (Figure 35). Finally, RNA was isolated from the left tibiae of diabetic 
vehicle and amisulpride injected mice and qRT-PCR performed to examine for levels of 
LOX. As expected, diabetic mice injected with only vehicle have profoundly decreased 
levels of LOX. However, with amisulpride injections for 4 weeks we observed a partial 
rescue in the expression of LOX in these diabetic mouse bones (Figure 36). These findings 
are fully consistent with our in vitro data and show for the first time that inhibition of 
dopamine signaling restores a normal collagen profile in diabetic bone most likely by 
restoring normal levels of collagen cross-linking via restoration of LOX expression, 
resulting in the healthy trabeculae we see in amisulpride treated mice. 
 
DISCUSSION 
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Part I: Sex-Linked Skeletal Phenotype of LOXL1 -/- Mutant Mice 
Results presented here indicate for the first time that LOXL1 is important for a 
normal trabecular bone phenotype, particularly in females. Serum analyses for pro-
collagen type I N-terminal propeptide (PINP) and C-terminal telopeptide for collagen 
type I (CTX-1) show not only an increase in CTX-1 marker for bone resorption in female 
LOXL1-/- mice, but also a decrease in PINP marker for bone formation. Differences in 
growth plate organization were evident in both LOXL1-/- females and males, although 
this effect was much more pronounced in females. The combination of the sex-specific 
defects in trabecular bone structure and an altered OPG/RANKL cytokine ratio suggest 
an osteoporotic-like condition in the LOXL1-/- female mouse bones. This is supported by 
previous studies in humans and animals showing that osteopenic diabetic bones contain 
lower levels of lysyl oxidase family-dependent cross-links and higher levels of advanced 
glycation endproducts (AGEs), as recently reviewed (Saito et al. 2006; Khosravi, Sodek, 
Faibish, et al. 2014).  
LOXL1 is expressed by chondrocytes 
It is of interest that in 13 week-old mice, LOXL1 expression was observed almost 
exclusively in and around chondrocytes and in the growth plate extracellular matrix in 
femurs. It has been previously reported that the expression patterns of all five LOX 
isoforms in fracture healing and identified a temporal expression pattern which implied 
high expression particularly in chondrocytes (Gerstenfeld et al. 2003).  LOXL2 
knockdown studies in the ATDC5 chondrocyte cell line identified a critical role for 
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LOXL2 expression in chondrocyte differentiation (Iftikhar et al. 2011).  LOXL1- LOXL4 
were all up-regulated during the chondrogenic phase of bone healing, but studies in 
ATDC5 cells indicated that LOXL1 expression as a function of differentiation was 
constitutive (Iftikhar et al. 2011).  Here, data in Figure 8 suggest that LOXL1 is critical 
for chondrocyte growth plate organization in both sexes, with greater effect and 
consequences on trabecular bone structure in female mice. Taken together, data suggest 
that while LOXL2 is required for chondrocyte differentiation, LOXL1 contributes to 
chondrocyte organization with apparent secondary effects on trabecular bone structure.  
LOXL2 null mice have recently been reported to be perinatal lethal with 50% penetrance, 
though no bone characterization was presented (Martin et al. 2015). 
Bone abnormalities in LOXL1 -/- mice are site dependent 
There are differences in the severity of the trabecular defects, suggesting that 
LOXL1 deficiency may affect long bones and vertebrae differently. For example, 
trabecular defects in the femur were overall more severe than in the vertebrae, with the 
vertebrae exhibiting no defects in trabecular spacing.  Connectivity density was ~50% 
lower in the femur relative to the vertebrae. In a typical osteoporosis model, the more 
profound trabecular bone deterioration is observed in the vertebrae, which have 
trabeculation through the entire length of the vertebral body and is the most common site 
of fracture (Tommasini et al. 2005). Our findings using LOXL1 null animals suggest that 
(i) LOXL1 plays crucial roles in bone remodeling that preferentially affect one site more 
severely than another, and (ii) absence of LOXL1 results in bone pattern defects that are 
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not typical of osteoporosis. This finding may be related to the possibility that LOXL1 is a 
major product of chondrocytes, and a relatively minor product of osteoblasts suggested 
by data in Figure 2. 
LOXL1 female specific bone pathology may be due to influences on sex hormones 
  The LOXL1 isoform has been thought to be most important in elastin 
biosynthesis, whereas direct evidence for a role for LOXL1 in skeletal structure has not 
been previously reported. The trabecular defects combined with the cytokine profiles 
reported here in the female LOXL1-/- mice suggest cross-talk between expression of 
lysyl oxidase isoforms and female hormonal regulation or activity. Estrogen increases the 
activity of LOX in vivo in aging mice that undergo estrogen therapy, and this leads to the 
acceleration of the maturation of collagen and elastin in the extracellular matrix (Sanada 
et al. 1978). Loss of estrogen in post-menopausal women is a main physiological cause of 
bone loss and subsequent osteoporosis in these women, leading to an increase in the 
incidence of fracture (Bord et al. 2003). The effects of estrogen loss on the trabecular 
bones of mice have also been demonstrated (Bouxsein et al. 2005). Estrogen exerts its 
anti-resorptive effects in bone by stimulating the expression of OPG in osteoblasts (Bord 
et al. 2003), resulting in the sequestration of RANKL from its receptor RANK on 
osteoclasts (Bord et al. 2003). Immunoassays performed here showed a significant 
decrease in OPG and a significant increase in RANKL in all female LOXL1-/- mice 
tested, but not in male LOXL1-/- mice. This dysregulation tips the scales in favor of 
increased bone resorption. However, because all mice were cycling and fertile, it is likely 
  
  
67 
that estrogen production from the ovary was similar among WT and LOXL1-/- females. 
Thus, low estrogen levels in LOXL1-/- female mice are not likely to have occurred or to 
have driven the phenotypic sex-specific effects observed here, although estrogen levels 
will need to be measured in the future. We speculate that the loss of LOXL1 in some way 
either interferes with female hormone responses, or that the higher level of androgens in 
males may induce high levels of LOX or other lysyl oxidase isoforms in bone and 
compensate for constitutive low levels of LOXL1 in female bones (Bronson et al. 1987). 
Further investigation into the sex-specific developmental and hormonal regulation of 
lysyl oxidase family members in bone is now of considerable interest. 
Evidence for increased bone resorption in female LOXL1 knockout bones was 
further supported by histological analyses including osteoclast and osteoblast number per 
bone surface (Ballanti et al. 1997). To further support the cytometric analysis and provide 
a serum read-out for bone turnover, PINP and CTX-1 serum levels were analyzed (Biver 
2012). It was especially important to examine CTX-1 since this peptide is the portion of 
type I collagen cleaved by osteoclasts during bone resorption (Garnero et al. 2003). CTX-
1 serum levels were significantly elevated in female LOXL1-/- mice compared to their 
wild-type counterparts, confirming the increase in osteoclast number is accompanied by 
an increase in osteoclast resorptive activity. Interestingly, PINP levels, a marker of bone 
formation (Vasikaran et al. 2011), were decreased in LOXL1-/- female mice compared to 
their wild-type counterparts, suggesting impaired bone formation. Taken together data 
indicate that dysregulation in the process of bone remodeling female mice in the absence 
of LOXL1.   
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LOXL1 deficiency does not affect cortical bone 
A trabecular phenotype was observed in LOXL1 null mice, but no significant 
cortical bone abnormalities were identified by µCT analyses. We speculate that LOXL1 
may be most important in bone remodeling rather than bone formation. The phenotype 
would therefore be more apparent in relatively young 13 week old mice in the trabecular 
structure which is more dynamic than the cortical bone. Analysis of expression and 
localization of LOXL1 in bone in developing and aging male and female mice could be 
informative in this context, and may uncover a period in which LOXL1 is expressed not 
only by chondrocytes, but also by osteoblasts. LOXL1 expression has been previously 
detected in MC3T3-E1-E1 cells in vitro (Atsawasuwan et al. 2005).   
LOXL1 is required for growth plate organization independent of sex 
Both LOXL1-/- female and male mice have severely impaired organization of 
chondrocytes within the distal femur growth plates compared to wild type, suggesting 
that LOXL1 influences growth plate development independent of sex. However body 
weights and femur lengths were unaffected in both LOXL1-/- female and male mice. 
Decreased bone growth characteristic of many chondrodysplasias results primarily from 
defects in chondrocyte proliferation and apoptosis in the proliferative zone of the growth 
plate (Gualeni et al. 2013; Wang et al. 2007). Notably, overall chondrocyte density and 
growth plate height were the same in the LOXL1-/- mice as in their wild-type 
counterparts; while chondrocyte organization was not normal. We have reported that 
LOXL2 is critically required for chondrocyte differentiation in a fracture healing model 
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for endochondral bone development (Iftikhar et al. 2011), and additional reports indicate 
that LOX influences cell differentiation independent of its role in collagen cross-linking 
(Atsawasuwan et al. 2005; Khosravi, Sodek, Xu, et al. 2014).  
Conclusion: Part I 
It is now clear that the lysyl oxidase family is multifunctional and may affect cell 
signaling directly (Vora, Palamakumbura, et al. 2010; Vora, Guo, et al. 2010; Lucero, 
Maki, and Kagan 2011). However, data presented here could also suggest that LOXL1 is 
somehow regulated by sex hormones such as estrogen or testosterone. Further 
mechanistic studies will be needed to elucidate the mechanisms by which loss of LOXL1 
can lead to observed bone phenotypes. 
 
Part II: Incretin Dysregulation of Lysyl Oxidase: A Novel Mechanism for Diabetic 
Osteopenia 
 
 Increased fracture risk due to diabetic osteopenia is now appreciated to be an 
exceedingly burdensome health problem. Not only are type II and type I diabetes on the 
rise (CDC report 2017), but with advances in treatments for diabetes, diabetics are living 
longer lives (Copenhaver and Hoffman 2017). Therefore it is of upmost importance that 
orthopedic research is able to keep up with the aging population of diabetic patients to 
ensure quality of life isn’t compromised due to increased bone fragility with age, 
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compounded with diabetes. Immobility due to fracture doesn’t just exacerbate the 
microvascular complications of diabetes, including increased risk for cardiovascular 
problems (Chawla, Chawla, and Jaggi 2016), it is financially burdensome to our 
healthcare system which has to take care of an incapacitated aging population. Increased 
hospitalization due to fracture is also financially an issue for diabetic patients who are 
already struggling to afford the treatments needed to live with this disease (Copenhaver 
and Hoffman 2017).  
 Treatments for diabetic osteopenia are not available because of a lack of 
understanding of the molecular mechanisms governing this disease. As stated many 
times, decreases in BMD do not explain the increased bone fragility and fracture risk 
associated with type I and especially type II diabetes, where increased BMD is actually 
seen in many of these patients (Vestergaard 2007), most likely due to increased weight 
bearing on bones as a result of a correlation of diabetes mellitus with obesity (Cao 2011). 
We therefore sought to identify a molecular mechanism for diabetic osteopenia using a 
mouse model for type I diabetes induced by multiple low doses streptozotocin. 
Streptozotocin causes the destruction of pancreatic β-cells due to its ability to be 
recognized and imported by GLUT2 receptors, resulting in the induction of DNA damage 
and subsequent apoptosis in these cells (Motyl and McCabe 2009a). Although this is a 
model for type I diabetes, which is caused by autoreactive CD4+ and CD8+ T-cell 
mediated destruction of pancreatic β-cells, it is still relevant to type II diabetes mellitus 
since both result in hyperglycemia. Furthermore, by eliminating confounding factors that 
occur in type II diabetes, such as increased circulating inflammatory factors due to 
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obesity-induced low grade inflammation (Wu and Huan 2008b), we can better identify 
the specific mechanisms occurring in bone that are a result of diabetes itself. In our 
diabetic mouse model, we show diabetic bone has impaired collagen structure, severe 
trabecular defects, and decreased LOX RNA levels that seem to be mediating diabetes’ 
effects on bone health.  
 Our results provide for the first time a specific molecular mechanism for diabetic 
osteopenia. Our initial signaling studies show the anabolic effects that the incretin GIP 
has on bone extends to increases in lysyl oxidase production by osteoblasts. This is also 
the first report to provide the specific signaling pathway by which GIP upregulates LOX 
in osteoblasts, and shows that this is dependent on both cAMP/PKA activity, as well as β-
catenin mediated activation of TCF/LEF promoter elements in the LOX promoter. In 
diabetes, the pancreas becomes insensitive to GIP, as evidenced by previous research 
showing circulating serum levels of GIP remain the same, but the pancreas no longer 
secretes insulin in response to GIP (Nauck et al. 1993; Holst et al. 2011). Previous studies 
have also shown that dopamine can inhibit glucose dependent insulin secretion in the 
pancreas by dampening cAMP production by pancreatic β-cells (Maffei et al. 2015). 
Bariatric surgery and the dopamine receptor 2 inhibitor amisulpride, both of which inhibit 
the activity of the anti-incretin dopamine, both result in increases in glucose stimulated 
insulin secretion in the pancreas (Roix et al. 2012; Chaudhry et al. 2016). We therefore 
sought to examine if dopamine was also involved in interfering with GIP signaling in 
bone in the context of diabetes. This study provides the first evidence of increased serum 
dopamine levels in diabetes, and further shows that dopamine can also inhibit GIP’s 
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ability to stimulate LOX expression in osteoblasts. Finally, treatment of diabetic mice 
with therapeutic doses of amisulpride can restore normal LOX levels, collagen structure, 
and most importantly a normal trabecular bone phenotype in our diabetic mice. This is 
not the first time already available therapeutic drugs designed for one purpose have been 
appropriated for another use (Crowle, Douvas, and May 1992; Bourque, Dluzen, and Di 
Paolo 2009). For a drug to be available on the market for treatment, it has to undergo 
stringent, time intensive clinical trials and various other tests to deem it safe for 
widespread use (Sun et al. 2017). Since amisulpride has already undergone most of these 
examinations in the context of treatment of psychosis (McKeage and Plosker 2004), its 
therapeutic use in diabetic patients can occur much faster than if this were an untested 
pharmacological agent. The reppropriation of drugs to treat multiple diseases is cheaper, 
and more importantly safer for everyone (Sun et al. 2017). This report is another example 
of the complex interconnectedness of the systems of the human body, and provides 
further evidence that the skeleton interacts with the pancreas, the gut, and the brain.  
 
GIP upregulates LOX in osteoblasts and this is dependent on both cAMP production, 
PKA enzymatic activity, and β-catenin mediated activation of the LOX promoter 
 Our results show that GIP upregulates LOX predominantly, with the other 4 
isoforms only showing modest upregulation. We also show that upregulation of LOX 
mRNA and protein is dependent on adenylyl cyclase production of cAMP and PKA 
enzymatic activity, as evidenced by our experiments showing pretreatment with both 
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adenylyl cyclase and PKA inhibitors reverses GIP stimulation of cAMP and increases in 
LOX mRNA, and protein. As stated previously, the receptor for GIP is a type II GPCR 
that acts through Gsα stimulatory G-proteins that upon dissociation from their associated 
GPCR act on adenylyl cyclase to stimulate it to make cAMP from ATP (Trzaskowski et 
al. 2012). The GIPR is expressed on osteoblasts (Bollag et al. 2000), and the Gsα 
pathway is well recognized in human bone diseases (Silva and Bilezikian 2015). 
Treatments targeting this pathway are indicative of the crucial roles for cAMP levels in 
regulating bone formation, growth, and repair (Sinha et al. 2016; Shenker et al. 1994). 
Previous studies have shown the addition of GIP to insulinoma or islet cells leads to a 
dose-dependent increase in intracellular cAMP by stimulation of adenylyl cyclase, and 
the adenylyl cyclase activator forskolin can stimulate insulin secretion in pancreatic β-
cells on its own (Tseng and Zhang 2000). In these papers, it was also shown that 
increases in cytosolic calcium do not result in any appreciable insulin secretion (Ding and 
Gromada 1997; Tsukiyama et al. 2006), suggesting that GIP acts specifically through 
cAMP as a second messenger in pancreatic β-cells. Previous studies have also shown GIP 
treatment of osteoblasts results in a dose dependent increase in cAMP (Mieczkowska et 
al. 2015). In addition, elevated intracellular cAMP induces the transcription of the LOX 
gene in fibroblasts (Choung et al. 1998) and vascular smooth muscle cells (Ravid et al. 
1999). While this is the first report to show that upregulation of LOX mRNA and protein 
expression is dependent on cAMP in osteoblasts, taken together previous literature 
supports our results.  
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Protein kinase A is the main target of cAMP, with 4 sites available for cAMP 
binding in the regulatory domain of this enzyme. Upon cAMP binding, the regulatory 
domain of this enzyme undergoes a conformational change to free the catalytic domain, 
which can then phosphorylate its various downstream targets (Glass et al. 1989). GIP has 
been shown to stimulate insulin secretion in mouse pancreatic β-cells through activation 
of PKA (Ding and Gromada 1997; Timper et al. 2016). Therefore there is precedence for 
the signaling pathway we are showing in our data. Furthermore, our data show that the 
mechanism for GIP signaling in osteoblasts is similar to that in pancreatic β-cells. Since 
the skeleton and pancreas both secrete factors that have reciprocal effects on each other, 
such as insulin and osteocalcin (Kanazawa 2015; Lecka-Czernik 2017), these findings are 
not surprising.  
 Wnt/β-catenin signaling is very important to bone development. β-catenin 
signaling is essential for pre-osteoblast differentiation and mineralized tissue homeostasis 
and induces the proliferation of pluripotent cells and pre-osteoblasts (Krishnan, Bryant, 
and MacDougald 2006). Following activation by a number of different upstream 
pathways, β-catenin accumulates in the cytosol and then translocates to the nucleus 
(Krishnan, Bryant, and MacDougald 2006). Main targets of β-catenin are transcription 
factors of the TCF/LEF family, with which β-catenin forms a complex to target TCF/LEF 
to their corresponding TCF/LEF response elements in the promoters of their various 
targets. Reductions in osteogenic TCF/LEF signaling can interfere with bone cell 
differentiation and bone formation as well (Manolagas and Almeida 2007). Our results 
show for the first time that knocking down β-catenin in osteoblasts results in reduced 
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lysyl oxidase protein levels, which may contribute to the reduced bone formation seen 
when this pathway is interrupted in bone cells. In addition, our lab previously reported 
that the canonical Wnt pathway ligand Wnt3a can up-regulate lysyl oxidase in bone 
marrow stromal cells (Khosravi, Sodek, Xu, et al. 2014). In this same paper it was 
reported that there are functional TCF/LEF cis-elements in the lysyl oxidase promoter, 
which was shown using TCF/LEF cis-element mutant LOX promoter luciferase reporter 
constructs designed by our laboratory (Khosravi, Sodek, Xu, et al. 2014). To study the 
role of β-catenin in GIP signaling in osteoblasts, these constructs or wild type control 
constructs were transfected into MC3T3-E1 cells and LOX promoter activity was 
measured in response to GIP treatment. Transcription from the LOX promoter was 
increased in response to 10 nM GIP treatment, confirming our previous in vitro studies 
showing an increase in LOX RNA and protein in response to GIP. This induction 
however was not seen in cells that were transfected with a construct with a mutation in a 
TCF/LEF conserved consensus sequence located -913 bp upstream of the transcriptional 
start site. Therefore our report describes for the first time a potential cis- element for GIP 
regulation of lysyl oxidase located – 913 to -906 upstream of the LOX transcriptional 
start site. To confirm this, a TOP/FLASH assay was performed which showed non-
mutated, inducible TCF/LEF elements can be activated by GIP treatment in osteoblasts.  
The contribution of β-catenin to the activation of the LOX promoter by GIP was 
evaluated by co-transfecting MC3T3-E1 cells with the wild type LOX promoter reporter 
construct and a shRNA β-catenin knockdown plasmid. Results show that cells with 
significantly reduced β-catenin protein levels were unable to induce a response from the 
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LOX promoter in response to GIP. Taken together, these promoter studies point to a β-
catenin dependent mechanism for GIP mediated increases in LOX expression in 
osteoblasts in which β-catenin/TCF/LEF transcription factor complexes activate 
TCF/LEF inducible cis-elements in the LOX promoter, resulting in increased 
transcription from the LOX promoter.  
A wide variety of peptide hormones utilize cAMP as their second messenger, and 
insulin and insulin-like growth factor-1 (IGF-1) have been shown to exert their effects 
through β-catenin/TCF (Jin and Liu 2008). Previous studies in pancreatic β-cells show 
that incretins signal through Wnt to activate β-catenin and TCF7L2 transcription factors 
to increase pancreatic β-cell proliferation (Liu and Habener 2008). Notably, PKA 
activation leads to β-catenin Ser675 phosphorylation, which prevents β-catenin 
ubiquitination and subsequent destruction, stabilizing β-catenin and allowing it’s 
accumulation in the cytoplasm, an event that is positively associated with increased β-
cat/TCF transcriptional activity (Chiang, Ip, and Jin 2012). This pathway can be 
stimulated by insulin and IGF-1 in endocrine L and K cells (Chiang, Ip, and Jin 2012). 
Based on our results and the previous studies cited above, we propose a novel pathway 
for GIP upregulation of lysyl oxidase in which 1) GIP binds to its receptor (a GPCR) 
causing the dissociation of the Gαs subunit 2) Gαs stimulates adenylyl cyclase to make 
cAMP from ATP, resulting in increased cytosolic cAMP levels 3) cAMP binds to the 
regulatory subunits of PKA, causing activation of the catalytic subunits  4) PKA 
phosphorylates β-catenin at Ser675, preventing ubiquitnation and allowing cytoplasmic 
accumulation 5) β-catenin translocates to the nucleus, forming a complex with TCF/LEF 
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transcription factors that bind to TCF/LEF inducible cis-elements in the LOX promoter, 
resulting in increased transcription from the LOX promoter (Figure 38).  
 We elucidated this pathway in order to find potential molecular targets for the 
treatment of diabetic osteopenia. The Wnt pathway is involved in lipid metabolism and 
glucose homeostasis, and mutations in the Wnt receptor LRP5 may lead to the 
development of diabetes and obesity (Liu and Habener 2010). In addition, mutations in 
TCF/LEF are associated with increased incidence of diabetes mellitus (Jin and Liu 2008). 
The dysregulation of the Wnt pathway in the context of diabetic osteopenia is now of 
considerable interest and should be further investigated. 
 
Lysyl oxidase haploinsuffiency further exacerbates the irregular collagen organization 
and trabecular abnormalities in diabetic mice 
 
 We initiated our in vivo studies using streptozotocin as a model for diabetic 
osteopenia to see if LOX +/- mice could resemble diabetic mice in their bone phenotype, 
which would indicate to us that decreased LOX activity could be mediating the decreased 
bone quality in diabetic mice. This was based on previous studies showing decreased 
enzymatic crosslinking in diabetic bone (Saito et al. 2006) and defects in mechanical 
properties in diabetic bone that correlate with a defect in the organic matrix as opposed to 
the mineral component (Xiao et al. 2018; Vestergaard 2007). Diabetic osteopenia has 
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unique characteristics that separate it from other bone disorders such as post-menopausal 
osteoporosis. Defects are seen predominantly in the trabecular bone, which is more 
metabolically active, with a higher turnover rate and is more responsive to growth factors 
and hormones (Kim et al. 2015) (Kemink et al. 2000). Therefore the trabecular bone is 
more responsive to what is occurring in other parts of the body, while the cortical bone is 
more stable and provides more of a structural function (Kim et al. 2015). This is 
interesting in light of mechanical testing used to evaluate bone strength is primarily based 
on defects in the cortical bone, while there are very few mechanical tests available to 
study material defects in the trabecular bone (Jungmann et al. 2011). The fact that the 
trabecular bone is more defective in diabetes therefore seems reasonable since trabecular 
bone is more likely to react negatively to a dysregulation of hormones and whole body 
homeostasis than the cortical bone. In addition, the most common fractures in diabetic 
osteopenia occur in the appendicular as opposed to the axial skeleton (McCabe, Zhang, 
and Raehtz 2011), which is very different from post-menopausal osteoporosis where 
micro-fractures in the vertebrae are a signature of the disease (Bouxsein et al. 2005). 
Interestingly, in a paper by Pachalis et al. where BAPN, the pan lysyl oxidase inhibitor, 
was used to induce osteolathryism, defects in cross-linking were restricted to newly 
formed bone in the trabecula (Paschalis et al. 2011). This study also shows that while the 
mineral component of these bones was not affected, the mechanical performance of the 
whole bone was still affected with decreases in maximum force to failure (Paschalis et al. 
2011), a similar situation to that seen in diabetic bone (Xiao et al. 2018).  
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Micro-CT results in our study on the femurs from LOX +/- and diabetic mice both 
show no differences in the cortical bone, but profound differences in the trabeculae. In 
terms of the ratio bone volume/total volume (BV/TV), which measures the amount of 
bone, both LOX +/- and diabetic mice showed similar decreases in trabecular bone 
volume compared to the wild-type, non-diabetic bone. In terms of connective density, 
which is a trabecula specific measure of the amount of solid connections in the trabecular 
meshwork (Bouxsein et al. 2010), both LOX +/- and diabetic mice also showed similar 
decreases compared to the wild-type. Neither diabetic or LOX +/- mice showed a 
difference in the number of trabeculae, with measures each connection as a unit 
(Bouxsein et al. 2010), but both showed an increase in trabecular spacing, which is an 
average of the diameter of the spacing between the trabecula and is a measure of porosity, 
which is a critical determinant of trabecular bone quality with increased trabecular 
porosity correlating highly with an increased in fracture risk (Bouxsein et al. 2010; Burr 
2002). Only diabetic mice showed a decrease in trabecular thickness, which measures the 
thickness of each unit of a trabecular connection (Bouxsein et al. 2010). Therefore our 
results indicate that LOX +/- mice resemble diabetic mice in their bone phenotype, with a 
restriction of defects to the trabecular bone and similar decreases in trabecular 
parameters. However, what truly emphasizes that LOX is involved in diabetic osteopenia 
were the results from the mice that were LOX +/- and diabetic. These mice showed a 
profound exacerbation of the defects in trabecular structure as seen in the 3-D tomogram, 
accompanied by increased changes in trabecular parameters. Decreases in BV/TV in 
diabetic, LOX +/- mice were significantly lower than in either diabetic or LOX +/- mice 
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and much lower than that of the non-diabetic, wildtype mice. This pattern was the same 
for connective density and trabecular spacing. In diabetic, LOX +/- mice, the trabecular 
number, which previously showed no difference in either LOX +/- or diabetic mice, 
became significantly different from the wild type non-diabetic counterpart. Of note, 
trabecular number was not significant in wild type mice that were only diabetic, 
suggesting that the number of trabecula in diabetic mice is only affected upon further 
decreases in LOX. Trabecular thickness however did not seem to worsen with LOX 
heterozygosity, as indicated by similar decreases in diabetic wildtype and diabetic LOX 
+/- mice, showing that trabecular thickness is independent of LOX. However all the other 
parameters are influenced by LOX heterozygosity, suggesting that LOX is either directly 
or indirectly involved in the osteopenia we are seeing in the diabetic mice. If LOX were 
not involved, we would not see a worsening in the diabetic phenotype with a decrease in 
LOX, as is the case with trabecular thickness. Furthermore, if LOX was not influenced by 
diabetes, we would not see a worsening in the osteolathyratic phenotype of the LOX +/- 
when the mice were also diabetic. Defects in the trabeculae of the vertebrae were the 
same as in the femur for LOX +/- and diabetic mice, and were worsened by a 
combination of the two. However, they were not as severe as defects in the femur, 
consistent with what is seen in diabetic patients (Kemink et al. 2000).  
These initial results show that deficiencies in LOX could account for the bone 
phenotype seen in diabetic osteopenia, and led us next to investigate the collagen 
structure. To reiterate, LOX is a collagen cross-linking enzyme and inhibition of LOX 
results in defects in collagen structure in bone (McNerny et al. 2015; Paschalis et al. 
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2011). Previous studies have reported that in diabetic bone the amount of collagen 
remains the same, but the cross-linking is decreased (Saito and Marumo 2015). Collagen 
cross-linking is known to have profound effects on collagen fibril organization and 
structure, with increased enzymatic crosslinking resulting in tighter packed collagen 
fibrils and a more organized collagen microstructure(Saito and Marumo 2015). Fibril 
diameter is known to affect bone formation not only in terms of providing bone the 
strength needed to resist mechanical forces as stated in the introduction, but in terms of 
crystallization properties, since mineral deposition during bone formation occurs between 
the D-periods of collagen fibrils and initial crystallization occurs here (Nair et al. 2013). 
A smaller fibril diameter would confer to hydroxyapatite crystals more room for this 
initial crystallization, while a larger diameter would restrict this process (Nair et al. 
2013). Therefore it was important to us to find a technique that would examine collagen 
structure and organization, not just the amount of collagen present, and therefore 
picrosirius red staining was chosen. As stated previously, this staining method combines 
picric acid, which can partially dissolve collagen fibrils that are exposed due to loose 
packing and are soluble in acid due to decreased collagen maturity, with sirius red dye 
that binds to collagen. The literature offers many interpretations for differences in 
birefringence profiles due to picrosirius red staining (Lattouf et al. 2014; Whittaker et al. 
1994). We chose to follow the interpretation by Junquiera et al. which states that the 
brightness of the birefringence corresponds to how much the stain was able to penetrate 
the collagen fibers due to increased acid digestion, and is therefore a measure of collagen 
fibril packing and maturity (Junqueira, Bignolas, and Brentani 1979b). Therefore bright 
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yellow is indicative of loosely packed, immature collagen bundles, while dull green 
means the stain was barely able to penetrate the collagen fibril due to tightly packed, 
mature and organized collagen. Other colors such as orange and red result from 
intermediate packing and maturity. It is important to note that properly organized 
collagen which creates a competent microstructure should have a mixture of both tightly 
and loosely packed collagen fibrils, and a multi-modal collagen fibril diameter profile is 
essential for connective tissue to resist various kinds of stress and strain (Christiansen, 
Huang, and Silver 2000). Therefore picrosirius red staining methods offer not only a way 
to discern the extent of packing and diameter as an indirect measure of the extent of 
cross-linking, but also allows us to measure collagen heterogeneity as a measure of a 
higher order structure.  
Our results show that in the diabetic and LOX +/- mice, there is a very different 
birefringence profile from that found in the wild-type, non-diabetic controls, including a 
lot of bright yellow staining and collagen that appears striated. There is also a loss of 
heterogeneity, with the collagen primarily appearing yellow and orange with very little 
green or red present. Therefore it appears in the diabetic and LOX +/- mice that the 
collagen is less mature and loosely packed, and has lost its higher order organization. 
This result is again exacerbated in diabetic mice that are also LOX haploinsufficient, 
confirming the pattern seen in the trabecular bone defects, and suggesting that defects in 
collagen fibril diameter and structure are mediated by LOX. This result agrees with 
recent papers that show increased LOX activity results in decreased collagen fibril 
diameter due to increased cross-linking of the fibers (Mieczkowska et al. 2015; Xiao et 
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al. 2018; Saito and Marumo 2015), as is an issue with certain fibrotic diseases where 
LOX is dysregulated (Rodriguez, Rodriguez-Sinovas, and Martinez-Gonzalez 2008). In 
the context of diabetes, our results also agree with the literature, which suggests diabetic 
osteopenia results not from defects in the amount of matrix, but in the quality of the 
matrix and by association the quality of the bone (Saito and Marumo 2015). Finally these 
initial phenotypic results corroborate the many papers that show that it is the organic 
matrix component of bone that is defective in diabetes (McCabe, Zhang, and Raehtz 
2011; Kemink et al. 2000; Botolin and McCabe 2007; Vestergaard 2007; Xiao et al. 
2018; Antonopoulou et al. 2013). This report is the first to show that this could be a direct 
result of a decrease in LOX mediated cross-linking activity. To further corroborate these 
results, mechanical testing will need to be performed on bones from our LOX +/-, 
diabetic mouse model. While three-point bending tests would be ineffective in studying 
diabetic bone because they only measure qualities of the cortical bone (Kim et al. 2015), 
experiments such as microindentation, which measure the properties of the organic 
matrix by measuring the plastic deformation of a material (Jungmann et al. 2011), could 
be better suited to study the mechanical properties of these bones.  
 
Diabetic mice display defects in osteoblast number and synthetic activity, which may or 
may not be affected by LOX 
 As stated in the introduction, a hallmark of diabetic osteopenia is low bone 
formation, which is characterized by decreased osteoblast number due to defects in 
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osteoblast differentiation (McCabe 2007). Decreased osteoblast number is not 
accompanied by decreased osteoclast number, which remains the same in diabetic 
osteopenia (Kalaitzoglou et al. 2016), tipping the normally balanced scale of overall bone 
turnover in favor of increased bone resorption. We therefore wanted to make sure our 
diabetic mouse model displayed this important pathological characteristic and also 
wanted to evaluate if LOX +/- had similar defects. Previous studies have shown that LOX 
has important influences on bone that extend beyond its role in crosslinking (Pischon et 
al. 2009; Vora, Palamakumbura, et al. 2010; Ravid et al. 1999). A study done by our lab 
showed that LOX is essential for creating a sufficient pool of osteoblast progenitor cells 
by increasing their proliferation, which needs to occur before differentiation (Khosravi, 
Sodek, Xu, et al. 2014). We therefore speculated that LOX could have another influence 
on diabetic osteopenia in terms of this novel function. We therefore examined femurs 
from our diabetic and LOX +/- mice histologically and immunostained for osteocalcin, 
which positively identifies mature, fully differentiated osteoblasts. Our diabetic mice 
showed a significant reduction in mature osteoblasts in the trabecular bone compared to 
non-diabetic controls, with very little positive staining seen in the area directly below the 
growth plate where most of the trabecular bone is located. This is typical of the low bone 
turnover osteopenia seen in diabetes and confirms our mouse model is recapitulating this 
phenotype. However, LOX +/- mice had normal osteoblast numbers, suggesting that 
mature osteoblast number is independent of LOX and that the role of LOX in diabetic 
osteopenia may be primarily related to its effects on collagen crosslinking. However, we 
also examined serum levels of PINP as a measure of osteoblast activity. Interestingly, 
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PINP levels do seem to be mediated by LOX, with LOX +/- and diabetic mice having 
similar reductions in serum PINP and diabetic, LOX +/- mice displaying a further 
decrease. This is interesting in light of the only other reported function of LOX in bone 
cells is to create more osteoblast progenitor cells (Khosravi, Sodek, Xu, et al. 2014), 
therefore we would expect to see this pattern reflected in decreased mature osteoblast 
numbers in LOX +/- mice. This reduction in osteoblast activity without a decrease in 
osteoblast number points to another influence of LOX on osteoblast activity that extends 
beyond both crosslinking and osteoblast progenitor proliferation. Further studies will 
have to be conducted to uncover the significance of this finding.   
 
Diabetic bone has decreased levels of LOX and diabetic osteoblasts do not produce or 
secrete detectable amounts of LOX  
 
 While decreased enzymatic crosslinking has been shown in diabetic bone (Saito et 
al. 2006), no one has looked at expression levels of lysyl oxidase. Based on our 
phenotypic analysis of the diabetic and LOX +/- bone showing that LOX is mediating 
further defects in collagen and trabecular structure in diabetic bone, we isolated RNA 
from the tibiae of the same mice used for micro-CT and picrosirius red analysis. Our 
results show a profound downregulation of LOX mRNA in diabetic bone, supporting our 
hypothesis that decreased LOX could be responsible for the decreased bone quality seen 
in diabetes. The decrease in LOX mRNA in diabetic bone is actually beyond that seen 
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even in LOX haploinsufficient mice that are only producing LOX from one allele, and 
explains why the differences in the bone phenotype between LOX +/- animals and 
diabetic LOX +/- are so apparent. In terms of the diabetic mice however, there is a 
discrepancy between the down-regulation of LOX in diabetic bone and the further 
decrease in bone quality with LOX haploinsufficiency. The difference in LOX expression 
levels between diabetic wildtype mice and diabetic LOX +/- mice is only about 6 fold, 
which doesn’t fully account for the increase in the severity of the phenotype in diabetic 
LOX +/- mice. Therefore there may be other mechanisms at work in diabetic osteopenia 
to cause the exacerbated phenotype that we are seeing, such as some indirect effect LOX 
downregulation has on other aspects of bone formation. However, the intensity of the 
down-regulation of LOX expression in diabetic bone can’t be ignored and therefore we 
pursued this line of research further.  
We next examined if the decreased levels of LOX in diabetic bone were a result 
of decreases specifically in osteoblast produced LOX, as opposed to some other cell type 
found in bone. We therefore isolated primary osteoblasts from diabetic and non-diabetic 
mice and measured expression levels of LOX RNA, as well as intracellular and secreted 
LOX. qRT-PCR results show that LOX is the predominant isoform expressed in 
osteoblasts, and is the most profoundly downregulated in osteoblasts isolated from 
diabetic mice, followed by LOXL1 which corroborates our studies on LOXL1 -/- mice. 
Diabetic osteoblasts are only expressing about 10% of the normal levels of LOX 
expressed by non-diabetic osteoblasts, which agrees with the downregulation of LOX we 
see in RNA isolated from diabetic bone. This is also reflected in the absence of 
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intracellular and secreted LOX protein in the Western blot, although the complete 
absence of LOX protein in diabetic osteoblasts seems slightly unreasonable. However, 
we isolated RNA and protein from primary cells after only three days in culture in hopes 
that they would maintain their diabetic profile, and did not change medium during this 
time. This may explain why in our Western blot the bands for secreted LOX are so 
intense for the non-diabetic osteoblasts, for after three days in culture non-diabetic 
osteoblasts are most likely secreting a large amount of LOX into the medium (Pischon et 
al. 2009). Therefore, it could follow that the intensity of the band for LOX in non-
diabetic osteoblast medium is overshadowing the detectable amounts of LOX in the 
diabetic primary osteoblasts, since the exposure used was maintained the same for all 
westerns to control for differences due to photographic processing, not actual protein 
levels. This experiment was repeated multiple times, with similar results. Therefore more 
sensitive methods should be used in the future to analyze the differences in LOX protein 
between non-diabetic and diabetic osteoblasts. However, our report is still the first to 
show that osteoblasts are not producing adequate amounts of LOX, which could have 
devastating effects on bone quality and strength.  
The results showing diabetic osteoblasts were able to maintain their diabetic 
profile after culture is also an interesting observation. When primary cells are cultured 
they tend to lose the characteristics they had in vivo (Geraghty et al. 2014), however the 
profound differences in LOX expression in osteoblasts isolated from diabetic mice were 
still present after three days in culture. While this is a short amount of time and it is 
reasonable to conclude that the osteoblasts would still maintain the characteristics they 
  
  
88 
had in the diabetic environment of the mouse, it is tempting to suggest the potential for 
epigenetic regulation of gene expression in diabetes in bone. This has been shown to 
occur in diabetes, where hyperglycemia can cause permanent and inheritable changes in 
gene expression profiles (Ling and Groop 2009; Jerram, Dang, and Leslie 2017), and is 
an exciting new direction in diabetes research that could offer new opportunities for 
therapeutics.  
Peripheral dopamine is increased in diabetes and can inhibit GIP signaling and LOX 
expression in osteoblasts 
 As stated in the Introduction, in diabetes pancreatic β-cells stop responding to GIP 
signaling (Holst et al. 2011). Since we have shown that GIP upregulates LOX in 
osteoblasts, and in diabetes osteoblasts stop producing LOX, we hypothesized that a 
similar situation was occurring in bone and causing the diabetic osteopenia we see in our 
diabetic mouse model. Many mechanisms for the inhibition of GIP signaling in diabetes 
have been explored in the literature (Nauck et al. 1993; Opinto, Natalicchio, and 
Marchetti 2013), including desensitization of the GIPR, which is a well characterized 
event in which, with prolonged exposure to a ligand, a receptor stops signaling (Tseng et 
al. 1996). This is due to the presence of G-protein receptor kinases or GRKs which 
phosphorylate GPCRs, leading to the binding of β-arrestin. β-arrestin binding results in 
the inability of the associated G-proteins to re-associate with the receptor and signal to 
their downstream effectors (Lohse et al. 1996). Binding of β-arrestin also initializes 
receptor internalization, resulting in fewer receptors being present at the surface of the 
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cell (Sarnago et al. 2003). We first explored this mechanism, but found that expression of 
GRK remained the same and the expression of GIPR was actually upregulated in diabetic 
bone (data not shown). In addition, studies have shown that serum excursions of GIP 
remain the same in diabetic patients (Kim and Egan 2008), therefore the prolonged 
exposure to a stimulus to initiate receptor desensitization is not present for the GIP ligand 
in diabetes. We therefore explored a different mechanism. As previously stated, the anti-
incretin dopamine is able to inhibit glucose stimulated insulin secretion in pancreatic β-
cells by antagonizing GIP stimulated cAMP increases (Maffei et al. 2015), and there is 
evidence that gut produced dopamine is responsible at least in part for the recovery from 
hyperglycemia seen in patients that have undergone bariatric surgery (Chaudhry et al. 
2016). However, there are no reports in the literature that examine if serum dopamine 
levels are dysregulated in diabetes. This is the first study to our knowledge that shows in 
a diabetic mouse model serum levels of dopamine are significantly increased compared to 
non-diabetic control animals. Therefore the role of increased dopamine in the pathology 
of diabetes is now of considerable interest, and future experiments should examine 
dopamine levels in diabetic humans. The role of dopamine in diabetes has only been 
extensively studied in the context of dopamine as a neurotransmitter, and its role in 
obesity (Sanjay et al. 2011; Lopez Vicchi et al. 2016).  
The signaling pathway we discovered for GIP in osteoblasts is very similar to that 
seen in pancreatic β-cells (Ding and Gromada 1997; Jin and Liu 2008). We therefore 
used previous studies done in pancreatic β-cells as a template to look at dopamine 
signaling in osteoblasts (Maffei et al. 2015). Our results show that, similar to pancreatic 
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β-cells, treatment of osteoblasts with dopamine inhibits GIP stimulated cAMP increases, 
thereby inhibiting the downstream pathway for the expression of LOX in osteoblasts. 
This result explains the decrease in LOX protein we see in osteoblasts with increasing 
concentrations of dopamine. This corroborates our previous results showing osteoblasts 
isolated from diabetic mice are hardly producing any LOX, and offers to our knowledge 
the first molecular mechanism for diabetic osteopenia. Given that 1) as little as 10 nM 
dopamine starts to inhibit GIP stimulated LOX production 2) there are significantly high 
serum levels of dopamine seen in the diabetic mice and 3) we see a severe, LOX 
mediated bone phenotype in diabetic mice, it is reasonable to conclude that in diabetes 
elevated dopamine is inhibiting proper bone formation by inhibiting LOX expression in 
osteoblasts.  
 
The dopamine receptor inhibitor amisulpride restores GIP signaling and LOX 
production in osteoblasts and in vivo administration of amisulpride reverses the 
osteopenia in diabetic mice 
 
 To confirm that decreased GIP signaling is specifically due to dopamine and not 
some other dysregulation in signaling in diabetes, we performed an experiment in which 
we attempted to rescue GIP signaling and LOX production in diabetic osteoblasts by 
pretreating primary cells freshly isolated from diabetic and non-diabetic mice with the 
dopamine receptor 2 inhibitor amisulpride. Dopamine has 5 receptors, all of which are 
  
  
91 
expressed on osteoblasts (Lee et al. 2015), but dopamine receptor 2 specifically is known 
to couple with Gαi/o inhibitory G-proteins that prevent adenylyl cyclase from making 
cAMP, which has been shown to occur in pancreatic β-cells (Rubi et al. 2005). 
Amisulpride is a specific dopamine receptor 2 (D2R) inhibitor, and has been shown to 
reverse dopamine’s inhibition of acetylcholine in the brain (Curran and Perry 2001). It is 
classified as an atypical anti-psychotic due to its potent and specific inhibition of D2R 
without any effect on other receptors in the brain, and is commonly prescribed to treat 
schizophrenia and dysthymia in Europe, although it is not an approved drug in the United 
States (Schoemaker et al. 1997). Interestingly, our primary cells isolated from diabetic 
mice were unable to respond to GIP with either increases in cAMP or increases in LOX 
expression. This not only supports our hypothesis that defects in the GIP upregulation of 
LOX are causing diabetic osteopenia, it provides evidence again for some epigenetic 
mechanism occurring in osteoblasts in diabetic conditions. There was no dopamine 
present in the medium of these cells to cause an inhibition of GIP, therefore it can be 
speculated that the osteoblasts had to maintain their expression profile from being 
exposed to dopamine in vivo. Again, it could very well be that the short culture time 
allows the cells to maintain their dampened signaling response to GIP, but it is tempting 
to conclude that diabetes is causing some permanent change in osteoblast gene 
expression. We also found that if diabetic osteoblasts were pretreated with amisulpride 
before treatment with GIP, there is a recovery in cAMP signaling and LOX expression. 
This confirms the specificity of the role of dopamine in inhibiting GIP signaling in bone 
in diabetes, and suggests that inhibition of dopamine signaling would likely restore bone 
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health in diabetes. Importantly, amisulpride by itself had no effect on LOX expression in 
untreated cells, indicating the ability of amisulpride to increase LOX expression is 
dependent on GIP.  
To test the hypothesis that amisulpride could possibly restore bone health in 
diabetes, we also administered our diabetic mice amisulpride via IP injections and 
examined their bones using micro-CT. To our surprise, 10 mg/kg of amisulpride daily for 
4 weeks was able to restore the trabecular bone architecture almost fully back to that of 
non-diabetic control mice, with increases in BV/TV, decreases in trabecular spacing, and 
increases in connective density, which were the parameters mediated by LOX in our 
diabetic, LOX +/- mice. There was also a restoration in collagen architecture and a 
restoration of normal LOX expression in the bones of the amisulpride injected diabetic 
mice, confirming the specific role of the organic matrix and lysyl oxidase in the 
pathology of diabetic osteopenia. This report is the first to offer potential therapeutic 
intervention for diabetic osteopenia, and suggests using a drug that has already been 
approved for use in humans. However, there are some issues that need to be addressed 
before amisulpride can be considered a potential treatment. First, our amisulpride 
injections were I.P. and therefore not specific to bone. This presents a problem because 
amisulpride is known to affect the brain by decreasing dopamine, which affects behavior 
and has well documented side effects such as uncontrolled movements, restlessness, 
insomnia, and weight loss (Welloma Pharmaceuticals). All of these side effects could 
potentially have an effect on bone (Hunter, Plaisance, and Fisher 2014; Niu et al. 2015). 
However, we monitored our mice closely for any changes in behavior and did not see any 
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significant changes in weight (Figure 38) among any of our mice at the dosage used. 
However, formal behavioral analysis will be needed in the future. Second, as stated in the 
introduction, amisulpride has also been shown to restore insulin secretion and lower 
blood glucose levels in diabetic mice (Roix et al. 2012), and deregulation of glucose 
homeostasis is a common feature in patients taking antipsychotics (Buse et al. 2003). In 
fact, on the pharmaceutical leaflet provided to patients taking amisulpride, it states that if 
the patient is diabetic, they must monitor their blood glucose and insulin very carefully 
(Welloma Pharmaceuticals). Clinically modest antidiabetic effects of amisulpride have 
been reported (Peuskens, De Hert, and Mortimer 2007), however there are no studies 
done on the effects of amisulpride in psychologically uncomplicated patients. However, 
there is still the possibility that recovery of a normal bone phenotype in our diabetic mice 
is simply due to a recovery of insulin secretion and reversal of hyperglycemia. To control 
for this, we also performed an insulin ELISA on our amisulpride injected diabetic mice 
and compared results to non-diabetic and diabetic vehicle injected mice. Insulin levels 
were slightly increased in our amisulpride injected mice, but not to significance from the 
vehicle injected diabetic mice and were still significantly lower than the non-diabetic 
control mice (Figure 39). Furthermore, blood glucose readings, while slightly decreased 
in our amisulpride injected mice, still remained in the diabetic range throughout the 
course of the study (Figure 40). In addition, the recovery we are seeing in the bone 
phenotype in amisulpride treated diabetic mice is relatively dramatic compared to 
untreated diabetic controls, and can’t be explained by the modest decreases we are seeing 
in blood glucose. Due to our careful monitoring of the mice and attempts to control for 
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dopaminergic effects in other parts of the body, the positive effect of dopamine inhibition 
on bone in diabetes is mostly likely due to a recovery in GIP signaling in bone. Still, 
dopamine’s effects on other parts of the body can’t be ruled out. Therefore other 
liabilities of amisulpride would have to be addressed before it could become a useful 
treatment for diabetic patients with osteopenia.  
Conclusion: Part II 
In conclusion, we have shown that GIP upregulates LOX in healthy osteoblasts. 
LOX is essential for maintaining the collagen network and subsequent integrity of bone. 
Under diabetic conditions however, this process is impaired due to increased peripheral 
dopamine that antagonizes GIP signaling in bone. This explains the faulty collagen 
framework and decreased trabecular bone quality seen in our model of diabetic 
osteopenia. Finally, we can restore diabetic bone back to healthy bone by inhibiting 
dopamine signaling using amisulpride treatment at therapeutic doses for one month.  
This study is novel and important in three major ways. First, it not only confirms 
previous studies that show the organic matrix is defective in diabetes, it provides 
evidence of the specific extracellular matrix enzyme that is being affected. Second, it 
demonstrates how important incretins and anti-incretins are to bone health independent of 
their effects on other parts of the body, and provides further evidence for the role of the 
gut-bone axis in the regulation of bone metabolism. Furthermore, our research shows that 
dopamine has effects on bone independent of its role as neurotransmitter, and is 
dysregulated in diabetes. While we focused on bone because that was the goal of the 
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project, it will be interesting to see if peripheral dopamine increases in diabetes affects 
other tissues. Third, by elucidating the mechanism for diabetic osteopenia, we are able to 
offer a potential treatment for this debilitating disease using a drug that is already being 
prescribed by clinicians, and is therefore known to be safe. Future work should be done 
on developing amisulpride as a therapeutic for diabetic osteopenia.  
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Table 1 
Left Femur Lengths in and Weights of Wild Type and Loxl1 -/- Mice 
Genotype Sex Mean Femur Length (mm) +/- SD Mean Weight (grams) +/- SD N 
Wild type Male 16.03 +/- 0.32 37.7 +/- 4.3 8 
Wild type Female 15.95 +/- 0.65 26.05 +/- 4.7 8 
Loxl1 -/- Male 16.23 +/- 0.17 36.21 +/- 3.14 8 
Loxl1  -/- Female 16.03 +/- 0.48 26.1 +/- 3.19 8 
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Table 2: Bone Volume/Total Volume (BV/TV) of Cortical Bone 
 
 
 
 
 
 
 
 
 
 
  
 
Male, 
LOXL1 +/+ 
Male, 
LOXL1 -/- 
Female, 
LOXL1 +/+ 
Female, 
LOXL1 -/- 
Femur 0.543 +/- .02 0.529 +/- .03 0.512 +/- .03 0.487 +/- .03 
Vertebrae 0.598 +/- .13 0.639 +/- .03 0.629 +/- .05 0.638 +/- .06 
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Table 3 
Wild-type and Mutant Sequences of TCF/LEF Elements in the Lysyl Oxidase 
Promoter. 
 
Mutated Site Wild-type sequence Mutant sequence 
Site #1: -913 to -906 AAGCTTTGTTCCC AAGCTTTGGCCCC 
Site #2: -1321 to -1328 CACCTTTGTTTAG CACCTTTGGCTAG 
Site #3: -1392 to -1385 TTTCTTTGAATTT TTTCTTTGGCTTT 
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Figure 1. Absence of LOXL1 in femur tissue from Loxl1 -/- mice. Genotyping of mouse 
tail tip DNA shows the presence of a single 175 bp band corresponding to the mutant 
gene and the absence of the larger band corresponding to the wild type LOXL1 gene. 
Genotype designations are under each lane. The marker is a 1 Kbp ladder. 
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Figure 2. Absence of LOXL1 in LOXL1-/- bones. LOXL1 antibody (Abbiotec #252215) 
or IgG isotype control were employed to stain femurs from LOXL1-/- mice and wild type 
littermates. Arrows mark the growth plates which contain high levels of LOXL1 staining 
in wild type mice.  LOXL1-/- femurs contain no LOXL1 staining.  Scale bars, 100 µm for 
100X magnification and 50 µm for 200X magnification. 
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 Figure 3. Micro-computed tomography of Loxl1-/- and wild type mouse bones.  Three-
dimensional images (transverse view) for the femoral distal metaphysis (A-D) 
representing wild type and LOXL1 -/- male and female mice. Images are representative 
of eight animals analyzed. (E-H) Images for L5 vertebrae (sagittal view) representing 
wild-type and LOXL1 -/- male and female mice. Images are representative of eight 
animals analyzed per group. (I-L) Representative full-length, cross-sectional views of the 
femur from wild type and LOXL1 -/- male and female mice showing the same overall 
length of femurs, but trabecular deficiencies in female mutant mice. 
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Figure 4. Trabecular bone parameters from femur distal metaphysis from wild type and 
LOXL1-/- male and female mice. Data are (mean values +/- SD). One asterisk (*) 
indicates significant difference from wild-type mice of the same sex with p<.01, two 
asterisks (**) indicate p<.001, and three asterisks indicate p<.0001 by one-way ANOVA 
and Tukey’s multiple comparison test; n=8 
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 Figure 5. Trabecular bone parameters from L5 vertebrae representing wild type and 
LOXL1-/- male and female mice. Data are (mean values +/- SD). One asterisk (*) 
indicates significant difference from wild-type mice of the same sex with p<.01, two 
asterisks (**) indicate p<.001, and three asterisks indicate p<.0001 by one-way ANOVA 
and Tukey’s multiple comparison test; n=8 
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Figure 6. TRAP staining of representative sagittal sections of femurs. (A-D) Images are 
from the area directly proximal to the distal growth plates representing wild type and 
LOXL1-/- male and female mice; scale bar, 200 µM. (E) Panel D at higher magnification 
(200X). Arrows indicate TRAP positive osteoclasts. Scale bar, 100 µM. 
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 Figure 7. (A) Histomorphometric analyses of histological sections of femur sections 
analyzed for number of TRAP positive osteoclasts in wild type and LOXL1-/- male and 
female mice. Data are (mean values +/- SD). One asterisk (*) indicates significant 
difference from wild-type mice of the same sex with p<.01, two asterisks (**) indicate 
p<.001, and three asterisks indicate p<.0001 by one-way ANOVA and Tukey’s multiple 
comparison test; n=8. (B) Histomorphometric analyses of histological sections of femur 
sections analyzed for number of osteoblasts. Asterisk notation is the same, n=8 (C) 
Calculated ratio of osteoclasts to osteoblasts. Asterisk notation is the same, n=8. 
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 Figure 8. Hematoxylin and eosin staining of representative sagittal sections of femur 
distal growth plates.  (A-D) Images are from wild type and LOXL1-/- male and female 
mice; scale bar, 100 μM. (E) Histomorphometric analyses of histological sections of 
femur sections for chondrocytes per column of wild type and mutant male and female 
mice. Asterisk notation is the same as in Figure 6, n=8. 
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 Figure 9. Concentration (pg/mL) of OPG, RANKL, interleukin 6, TNF-α, and 
osteocalcin in the serum of wild type and LOXL1-/- male and female mice at 13 weeks of 
age.  Data are mean values in pg/ml +/- SD.  One asterisk (*) indicates significant 
difference from wild-type mice of the same sex with p<.01, two asterisks (**) indicate 
p<.001, and three asterisks indicate p<.0001 by one-way ANOVA and Tukey’s multiple 
comparison test; n=8. 
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Figure 10. Concentration (pg/mL) of CTX-1 (A) and PINP (B) in the serum of wild type 
and LOXL1-/- male and female mice. Data are mean values in pg/ml +/- SD.  One 
asterisk (*) indicates significant difference from wild-type mice of the same sex with 
p<.05 and two asterisks (**) indicate p<.01 by one-way ANOVA and Tukey’s multiple 
comparison test; n=8. 
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Figure 11. LOX paralogue regulation by 24 hr treatment with GIP in A) MC3T3-E1 
osteoblasts and B) primary osteoblasts (pooled from 5 mice) after 24 hours. Data were 
calculated using the 2-(ΔΔCT) method and are represented as fold change relative to 
GAPDH.  Data are means +/- SD, *p<0.05, **p<0.01, ***p<0.001 from untreated by 
One-way ANOVA with Tukey’s multiple comparisons test.  
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Figure 12. RIA Analysis of cAMP production. MC3T3 osteoblasts were treated with GIP 
for 4 hours in the presence of IBMX (phosphodiesterase inhibitor). SQ22536= adenylyl 
cyclase inhibitor. Forskolin= adenylyl cyclase activator (positive control). Data are means 
+/- SE, *p<0.05, **p<0.01, ***p<0.001 indicate difference from untreated, while 
#p<0.05, ##p<0.01, and ###p<0.001 indicate difference from 10 nM GIP by One-way 
ANOVA and Tukey’s multiple comparisons test. 
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 Figure 13. CREB phosphorylation after GIP treatment for 15 minutes. Cell lysates were 
probed with antibodies recognizing PKA phosphorylation site Ser133 on CREB and total 
endogenous CREB. Cells treated with the PKA inhibitor PKI-22 were pretreated with the 
inhibitor for 30 minutes prior to GIP treatment. This experiment was repeated three times 
and data are means +/- SE, *p<0.05, **p<0.01, ***p<0.001 indicating differences from 0 
nM untreated by One-way ANOVA and Tukey’s multiple comparisons test; asterisks 
above the bars indicate differences between groups. 
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 Figure 14.  RT-PCR for LOX RNA transcripts. Treatment of MC3T3 osteoblasts with 
GIP for 4 hours resulted in increased LOX RNA, which is reversed when cells were 
treated with the adenylyl cyclase inhibitor SQ22536 and the PKA inhibitor PKI 14-22. 
Data were calculated using the 2-(ΔΔCT) method and are represented as fold change relative 
to GAPDH. Data are means +/- SE, *p<0.05, **p<0.01, ***p<0.001 indicate difference 
from untreated, while #p<0.05, ##p<0.01, and ###p<0.001 indicate difference from 10 
nM GIP by One-way ANOVA with Tukey’s multiple comparison test.  
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 Figure 15. Western Blot for LOX intracellular protein expression. MC3T3 osteoblasts 
were treated with GIP for 4 hours and LOX protein expression was determined. Cells 
were also pre-treated with the adenylyl cyclase inhibitor SQ22536 and the PKA inhibitor 
PKI 14-22. β-actin was employed as loading control.  
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 Figure 16. Luciferase activity from the LOX promoters in response to GIP treatment in 
MC3T3 cells. A potential cis- element for GIP regulation of Lysyl oxidase is located – 
913 to -906 upstream of the LOX transcriptional start site. The fold change of lysyl 
oxidase transcriptional activity of wild-type and mutated reporter constructs in response 
to GIP. Data are pooled from three independent experiments (Data are means +/- SE, 
*p<0.05, **p<0.01, ***p<0.001 by One-way ANOVA followed by Tukey’s test for 
multiple comparisons).  
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 Figure 17. TOP/FLASH assay for TCF/LEF promoter element response to GIP 
treatment in MC3T3 calvarial osteoblasts. TCF/LEF promoter elements show an increase 
in transcriptional activity in response to GIP treatment. Data are represented as a ratio of 
luciferase to renilla RLUs and are pooled from three independent experiments (Data are 
means +/- SE, *p<0.05, **p<0.01, ***p<0.001 by One-way ANOVA followed by 
Tukey’s test for multiple comparisons) 
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 Figure 18. β-Catenin shRNA inhibits GIP stimulated LOX promoter activity A) Fold 
change in transcriptional activity in reference to control (non-treated) cells. Data are 
pooled from three independent experiments (Data are means +/- SE, *p<0.05, **p<0.01, 
***p<0.001 by One-way ANOVA and Tukey’s test for multiple comparisons). B) 
Western Blot confirmation of β-catenin knockdown in cell lysates from MC3T3 cells.  
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Figure 19. β-Catenin shRNA knockdown osteoblasts have decreased LOX protein 
expression. Western blot analysis of LOX protein in β-catenin knockdown cell lysates 
from shRNA transfected MC3T3 cells.  
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 Figure 20. Bone phenotype of non-diabetic and diabetic wild type and LOX +/- 
femurs. Micro-CT 3-D tomogram (A) and trabecular bone parameters (B) from distal 
metaphysis of the femur in non-diabetic and diabetic wild type and LOX +/- mice.  
Asterisks (*) under brackets are vs. wild type; *p<0.05; **p<0.01, ***p<0.001 by One-
way ANOVA and Tukey’s test for multiple comparisons. Asterisks (*) above brackets 
indicate differences among diabetic mice; n=6 
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 Figure 21. Cortical bone volume/total volume from distal metaphysis of the femur in 
non-diabetic and diabetic wild type and LOX +/- mice.  One-way ANOVA and Tukey’s 
test for multiple comparisons was employed for analysis, n=6 
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Figure 22. Bone phenotype of diabetic, LOX +/-, and diabetic LOX +/- mice L5 
vertebrae. Micro-CT 3-D tomogram (A) and trabecular bone parameters (B) from 
vertebral trabecular compartment in diabetic and LOX +/- mice.  Asterisks (*) under 
brackets are vs. wild type; *p<0.05; **p<0.01, ***p<0.001 by One-way ANOVA and 
Tukey’s test for multiple comparisons. Asterisks (*) above brackets indicate differences 
among diabetic mice; n=6. Only parameters that showed significance are shown.  
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 Figure 23. Diabetic mice have reduced osteoblast numbers typical of a low bone 
turnover osteopenia. Osteocalcin immunostaining of representative sagittal sections of 
femur in the trabecular area directly proximal to the distal growth plates in diabetic and 
wild type mice. Arrows indicate osteocalcin positive osteoblasts (cuboidal cells). IgG 
isotype controls and LOX +/- mice resemble the wild-type, n=6, 3 sections per animal 
 
 
 
 
 
 
  
  
122 
Figure 24. LOX +/- mice have decreased anabolic activity, but not osteoblast number A) 
Histomorphometric analyses of histological sections of femur sections analyzed for 
number of osteocalcin positive osteoblasts and B) TRAP stained osteoclasts. C) 
Concentration (pg/mL) of PINP in the serum of wild type and diabetic mice. Data are 
means +/- SD, n=8. Asterisks (*) are vs. wild type; *p<0.05; **p<0.01, ***p<0.001 by 
One-way ANOVA with Tukey’s test for multiple comparisons.  
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 Figure 25. Collagen profile analysis of non-diabetic and diabetic, LOX +/-, and 
diabetic/LOX +/- mice. Picrosirius red staining of collagen under non-polarized (left 
panel) and polarized light (right panel) in the femur. Representative images are shown, 
n=6 with three sections per animal. 
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 Figure 26. Expression of LOX is downregulated in diabetic bone in vivo. RNA was 
isolated directly from right femurs. Data represent fold change calculated using the 2-
(ΔΔCT) method relative to wild type, non-diabetic controls; *p<0.05, **p<0.01, 
***p<0.001 by One-way ANOVA and Tukey’s test for multiple comparisons.  n=6 per 
group. 
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Figure 27. qRT-PCR for common osteoblast expressed mRNA transcripts. Primary bone 
explant cells were incubated in osteogenic differentiation medium (100 nM 
dexamethasone, 0.05 mM L-ascorbic acid, 10 mM β-glycerolphosphate) for 3 weeks and 
medium changed every 3 days. RNA was isolated after three weeks. Data represent fold 
change in reference to RNA isolated from primary bone cells at day 4. Data are 
calculated using the 2 -(ΔΔCT) method using GAPDH reference gene. N=5 per group 
(diabetic and non-diabetic).  
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Figure 28. Diabetic primary bone cells have decreased LOX RNA A) Absolute 
quantification of LOX isoforms in non-diabetic primary bone cells. Data were calculated 
based on a standard curve of known transcript copy numbers and normalized to the 
amount of cDNA added. B) Relative quantification of LOX isoforms in diabetic primary 
bone cells. Data represent percent of non-diabetic controls calculated using the ΔΔCT 
method using GAPDH internal control. Data are pooled from three independent 
experiments (Data are means +/- SE, *p<0.05, **p<0.01, ***p<0.001 by One-way 
ANOVA and Tukey’s test for multiple comparisons). N=5 per group (diabetic and non-
diabetic). 
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 Figure 29. Intracellular and secreted LOX protein levels are decreased in primary bone 
cell cultures. Primary bone cells were plated at density of 5 x 103 cells per cm2 in 10 cm 
plates, lysed after 4 days, and cell lysates were probed for LOX via Western Blot. 
Medium from the same plates was concentrated 40x and also assessed for LOX protein. 
N=4 per group with each lane representing a separate mouse. 
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 Figure 30. Diabetic mice have increased serum dopamine levels. Serum was isolated 
from blood taken from STZ induced diabetic and vehicle control mice. Concentration of 
dopamine (ng/mL) was increased in diabetic mice. Data are means +/- SD, *p<0.05, 
**p<0.01, ***p<0.001 by student’s T-test, n=10 per group. 
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Figure 31. Dopamine (DA) inhibits GIP stimulated cAMP increases. Treatment of 
MC3T3 cells with 10nM GIP for 4 hours results in an increase in cytosolic cAMP levels. 
Pretreatment for 30 minutes with 10-100 uM DA reverses this increase, suggesting DA is 
able to antagonize GIP stimulated cAMP production from adenylyl cyclase. Data are 
means +/- SD,*p<0.05, **p<0.01, ***p<0.001 from 0 nM DA treated with GIP, # 
difference from untreated by One-way ANOVA and Tukey’s test for multiple 
comparisons. 
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 Figure 32. Western blot of cell extracts for LOX after GIP treatment for 4 hours, and/or 
pre-treatment for 30 minutes with various concentrations of Dopamine (DA) in MC3T3 
calvarial osteoblasts. Mouse osteoblasts were grown to 80% visual confluence, plated in 
6 well plates, and were serum starved for 18 hours prior to treatment. Cell layers were 
extracted directly in to sample buffer and western blots were probed for total LOX 
protein. 
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Figure 33. Inhibiting D2R Restores GIP stimulated cAMP production and LOX 
expression in diabetic primary bone cells. A) RIA Analysis of cAMP Production and B) 
RT-PCR for LOX RNA transcripts from primary bone cells isolated from diabetic and 
non-diabetic mice. Primary Bone Cells were treated with 10 nM GIP and/or pretreated for 
30 minutes with 20 µM Dopamine Receptor 2 inhibitor Amisulpride. Data are means +/- 
SD, #p<0.01, ##p<0.005, ###p<0.001 difference from untreated non-diabetic or diabetic 
control, *p<0.05, **p<0.01, ***p<0.001 difference between groups by One-way 
ANOVA with Tukey’s test for multiple comparisons. Data are from pooled primary cells 
from 5 diabetic and 5 non-diabetic mice. 
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Figure 34. In vivo IP administration of the D2R inhibitor amisulpride restores a normal 
bone phenotype in diabetic mice A) Micro-CT 3D tomographic reconstruction of femoral 
distal metaphysis in non-diabetic control, and diabetic vehicle or amisulpride injected 
mice. B) Trabecular parameters that showed significance by One-way ANOVA and 
Tukey’s test for multiple comparisons, N=3. 
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Figure 35. Collagen profile analysis of non-diabetic and diabetic vehicle or amisulpride 
injected mice. Picrosirius red staining of collagen under non-polarized (left panel) and 
polarized light (right panel) in the femur. Images are representative, with n=3 and three 
sections analyzed per animal. 
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 Figure 36. Expression of LOX is rescued in diabetic bone treated with amisulpride in 
vivo. RNA was isolated directly from right tibiae. Data represent fold change calculated 
using the 2-(ΔΔCT) method relative to wild type, non-diabetic controls; *p<0.05, **p<0.01, 
***p<0.001 by One-way ANOVA with Tukey’s test for multiple comparisons,  n=10 per 
group. 
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Figure 37. Summary of the signaling pathway for GIP upregulation of LOX in 
osteoblasts. 1) GIP binds to its receptor (a GPCR) causing the dissociation of Gsα subunit 
2) Gsα stimulates adenylyl cyclase to make cAMP from ATP 3) cAMP binds to the 
regulatory subunits (R) of PKA, causing activation of the catalytic subunits (C)  4) PKA 
phosphorylates β-catenin at Ser675, preventing ubiquitination and allowing cytoplasmic 
accumulation 5) β-catenin translocates to the nucleus, forming a complex with TCF/LEF 
transcription factors that bind to TCF/LEF inducible cis-elements in the LOX promoter, 
resulting in increased transcription from the LOX promoter 
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Figure 38. Descriptive analysis of weight in non-diabetic, diabetic vehicle, and 
amisulpride injected diabetic mice. 
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Figure 39. Amisulpride injected diabetic mice do not have increased serum insulin levels 
levels. Serum was isolated from blood taken from non-diabetic control, and amisulpride 
or vehicle injected diabetic mice. Concentration of dopamine (ng/mL) is increased in 
diabetic mice. Data are means +/- SD, *p<0.05, **p<0.01, ***p<0.001 by student’s T-
test, n=10 per group. 
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Figure 40. Descriptive analysis of blood glucose in non-diabetic, diabetic vehicle, and 
diabetic amisulpride injected mice.  
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